

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
20 December 2001 (20.12.2001)

PCT

(10) International Publication Number
WO 01/96565 A2

(51) International Patent Classification⁷: **C12N 15/12**,
15/18, 15/24, 15/62, C07K 14/54, 14/61, 14/715, 14/72,
A61K 38/17

Medicine, Infection & immunity, Medical School, F Floor,
Beech Hill Road, Sheffield S10 2RX (GB).

(21) International Application Number: PCT/GB01/02645

(74) Agent: **HARRISON GODDARD FOOTE**; Belgrave
Hall, Belgrave Street, Leeds LS2 8DD (GB).

(22) International Filing Date: 18 June 2001 (18.06.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0014765.2 16 June 2000 (16.06.2000) GB
0105969.0 10 March 2001 (10.03.2001) GB
0106487.2 16 March 2001 (16.03.2001) GB

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK,
SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA,
ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (*for all designated States except US*): **ASTERION LIMITED** [GB/GB]; Firth Court, Western Bank,
Sheffield S10 2TN (GB).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **ROSS, Richard**
[GB/GB]; Clinical Sciences, Northern General Hospital,
Sheffield S5 7AU (GB). **ARTYMIUK, Peter** [GB/GB];
University of Sheffield, Biology and Biotechnology Dept.
of Molecular, Sheffield S10 2TN (GB). **SAYERS, Jon**
[GB/GB]; University of Sheffield, Division of Genomic

Published:

— without international search report and to be republished
upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

WO 01/96565 A2

(54) Title: **BINDING AGENT**

(57) Abstract: This invention relates to agents which bind to cell surface receptors; methods to manufacture said agents; therapeutic compositions comprising said agents; and screening methods to identify novel agents.

BINDING AGENT

FIELD OF THE INVENTION

This invention relates to agents which bind to cell surface receptors; methods to
5 manufacture said agents; therapeutic compositions comprising said agents; and screening
methods to identify novel agents.

BACKGROUND OF THE INVENTION

10 Intercellular and/or intracellular signalling via receptor mediated activation of
biochemical and/or molecular mechanisms is a fundamental process for regulating
cellular and/or tissue homeostasis. Typically, ligands which interact with receptors to
bring about a suitable biochemical response are known as agonists and those that
prevent, or hinder, a biochemical response are known as antagonists. For example, and
not by way of limitation, cell specific growth factors are ligands that act as agonists and
15 bind receptors located at the cell surface. Activation of the receptors by ligand-specific
binding promotes cell proliferation via activation of intracellular signalling cascades that
result in the expression of, amongst other things, cell-cycle specific genes, and the
activation of quiescent cells to proliferate. Growth factors may also activate cellular
differentiation.

20

A large group of growth factors, referred to as cytokines, are involved in a number of
diverse cellular functions. These include, by example and not by way of limitation,
modulation of the immune system, regulation of energy metabolism and control of
growth and development. Cytokines which are secreted by lymphocytes are termed
25 lymphokines (also known as interleukins). Those secreted by monocytes and
macrophages are termed monokines. Cytokines are also secreted by endocrine glands,
(for example growth hormone (GH) by the pituitary gland), and adipose cells (for
example leptin). Cytokines mediate their effects via receptors expressed at the cell
surface on target cells.

30

CONFIRMATION COPY

Receptors of the cytokine receptor family possess a single transmembrane domain and lack intrinsic enzyme activity (1). Upon the binding of a cytokine to a cognate receptor, either receptor homo- or hetero-dimerisation or oligomerisation occurs. The receptor complex is internalised and signalling occurs through the activation of associated signalling cascades that include the Jak/Stat and Mapk pathways. Internalisation is followed by a recycling step whereby the receptor molecule is regenerated for further use within the cell.

The study of receptor/ligand interactions has been facilitated by the ability to define the structures of receptor molecules and their ligands. Several approaches, including X-ray crystallography and computer modelling, have greatly facilitated our understanding of the biology of ligand: receptor binding.

An example of the above is described with respect to GH and its binding to the growth hormone receptor (GHR). This example is merely meant to be illustrative and not limiting and is an example of a cytokine which activates a signal transduction cascade by binding, dimerisation and internalisation of the receptor:ligand complex.

It is known that a single molecule of growth hormone (GH) associates with two receptor molecules (3-6). This occurs through two unique receptor-binding sites on GH and a common binding pocket on the extracellular domain of two receptors. Site 1 on the GH molecule has a higher affinity than site 2, and receptor dimerization is thought to occur sequentially with one receptor binding to site 1 on GH followed by recruitment of a second receptor to site 2.

The extracellular domain of the GHR exists as two linked domains each of approximately 100 amino acids (SD-100), the C-terminal SD-100 domain being closest to the cell surface and the N-terminal SD-100 domain being furthest away. It is a conformational change in these two domains that occurs on hormone binding with the formation of the trimeric complex GHR-GH-GHR (Fig 5). It has been proposed that

ligand-driven receptor dimerization is the key event leading to signal activation (3), triggering phosphorylation cascades that include the Jak2/Stat5 pathway (7). Using confocal microscopy and Frequency Resonance Energy Transfer (FRET) it is known that there is very rapid internalisation of GHR after ligand binding and that internalisation and signalling are independent functions (16). Internalisation of the GHR-GH-GHR complex is followed by a recycling step whereby the receptor molecule is regenerated for further use within the cell.

The importance of receptor dimerization in signal transduction is indicated by a number of experiments. High concentrations of GH, which favour the monomeric GH-GHR complex, inhibit the GH signal (8). Mutations in the inter-receptor dimerization domain inhibit signalling without influencing GH binding (10). The strongest evidence comes from work with a GH molecule mutated at site 2 to prevent receptor dimerisation. These GH mutants block GH-stimulated cell proliferation (8,11-14), the conformational change associated with receptor dimerization (15), and Jak-Stat signalling (16).

US 5,849,535 describes a human growth hormone including a number of amino acid substitutions which disrupt Site 2 binding. The substitution of a different amino acid at G120 is one modification that disrupts Site 2 binding and the hGH variant acts as an hGH antagonist.

The in vivo efficacy of hGH and hGH variants is determined, in part, by their affinity for the hGH receptor and rate of clearance from the circulation. The kidneys are relatively small organs which receive approximately 25% of cardiac output. The kidneys perform several important functions primarily related to the regulation of the composition and volume of body fluids. The kidneys filter about 100 litres of plasma every day and of the blood flow in and out of a kidney only approximately 1% becomes urine. Approximately 20% of the plasma that passes through the kidney gets filtered into the nephron. Filtration takes place in the glomerulus which is driven by the hydrostatic pressure of the

blood. Water and small molecules are filtered whereas blood cells and large molecules, for example polypeptides, do not pass through the glomerular filter.

Those polypeptides with an effective molecular weight above 70 kDa are not cleared by
5 glomerular filtration because they are simply too large to be filtered. Certain proteins of small molecular weight are filtered by the glomerulus and are found in the urine. For example, Growth Hormone (GH has a molecular weight of 22.1 kDa and the kidney is responsible for clearing up to 60-70% of GH in humans (Baumann, 1991; Haffner et al, 1994), and up to 67% in rat (Johnson & Maack, 1977). Other examples of relatively
10 small molecular weight polypeptides which are filtered by the kidney include leptin, erythropoietin, and IL-6.

Syed *et al* (1997) constructed an anti-coagulant fusion protein which fused hirudin with albumin. This fusion protein showed extended plasma half life whilst maintaining a
15 potent anti-thrombin (anti-coagulant) activity. This is likely to result from decrease in glomerular filtration by the kidneys. However a problem associated with this strategy is that hirudin is a foreign protein and which is known to provoke a strong immune response. The increase in molecular weight of the hirudin fusion protein increases the catabolic half-life from 0.7 hours to 4.6 days.

20

A further method to increase the effective molecular weight of proteins and to produce a product which has reduced immunogenicity is to coat the protein in polyethylene glycol (PEG). The *in-vivo* half-life of GH has been increased by conjugating the proteins with poly ethylene glycol, which is termed "pegylation" (See Abuchowski et al., *J.Biol*
25 *Chem.*, 252:3582-3586 (1977). PEG is typically characterised as a non-immunogenic uncharged polymer with three water molecules per ethylene oxide monomer. PEG is believed to slow renal clearance by providing increased hydrodynamic volume in pegylated proteins (Maxfield et al., *Polymer*, 16:505-509 (1975)). US 5,849,535 also describes humanGH (hGH) variants which are conjugated to one or more polyols, such
30 as poly(ethylene glycol) (PEG).

An alternative to pegylation which provides a molecule which retains biological activity and is immune silent is herein disclosed. A chimeric protein comprising the extracellular domain, or part thereof, of a receptor linked, via a variable flexible linker molecule to its cognate ligand to produce an agent with an apparent molecular weight greater than the native ligand. In the example provided, GH is fused to at least part of the growth hormone receptor (GHR) which gives an approximate molecular weight of 55kDa which when glycosylated increases the effective molecular weight to approximately 75kDa. This would be of sufficient size to prevent the chimera being filtered by the kidney and, importantly, the molecule retains biological activity.

10

A long-acting form of growth hormone could be used in the treatment of both childhood and adult onset growth hormone deficiency. Growth hormone has well known anabolic actions and a long-acting form of growth hormone could be used for the treatment of a number of conditions by virtue of its anabolic actions including promoting growth in Turner's syndrome, renal failure, osteoporosis and muscle wasting in catabolic patients. Bovine somatotropin is currently used to enhance milk production from cows. A long-acting form of growth hormone would be an effective treatment for increasing milk yield from cows (Peel et al. 1981).

20 This strategy is applicable to other ligand-receptor combinations (eg. leptin, erythropoietin and IL-6). For example, leptin is being trialed as a therapy for obesity (Mantzoros & Flier, 2000). A long-acting form of leptin could be used to treat obesity, insulin resistance, hyperlipidaemia and hypertension. Erythropoietin is important in the generation of red cell mass. A long-acting form of erythropoietin could be used to treat anaemia especially that associated with renal failure.

Truncated GH receptors, which lack the cytoplasmic domain of the receptor, act as dominant negative inhibitors of GH signalling (9,19). The truncated receptor is expressed at a high level on the cell surface because it lacks the cytoplasmic domain essential for internalisation (16). In the presence of GH, the truncated receptor

heterodimerises with the full length receptor and blocks signalling because it lacks the cytoplasmic domain. As the truncated receptor fails to internalise it acts as a dominant negative inhibitor preventing internalisation of the GH receptor complex.

- 5 The disorders of acromegaly and gigantism result from an excess of growth hormone, usually due to pituitary tumours. A drug currently under trial is the pegylated GH antagonist B2036, designed using recently acquired knowledge of the molecular structure of the growth hormone receptor (GHR). Unfortunately, high levels of B2036 are required to antagonise GH action with drug levels over a 1000 times higher than
10 endogenous GH levels (18).

B2036, despite having a mutated site 2, binds to a receptor dimer, and is internalised in an identical fashion to GH. It does not however trigger the conformational change required for signalling. The high dose requirement of the antagonist relates to its
15 internalisation and its differential binding to soluble and membrane bound receptor. The pegylated antagonist does not bind efficiently to membrane bound receptor although pegylation increases half-life and lowers immunogenicity. The non-pegylated antagonist is rapidly internalised and cleared.

- 20 There is a need to provide an antagonist that is not internalised by the cell and that can be delivered in lower doses. This would prove a more effective and potent antagonist and provide a more effective and economical treatment.

The leptin receptor (28) and erythropoietin (EPO) receptor (29,30) share considerable
25 structural homology to the GHR and require a similar dimerisation process to trigger signalling. Leptin suppresses appetite and leptin resistance is associated with obesity. A leptin receptor antagonist will provide a treatment for anorexia nervosa. EPO excess causes polycythaemia which may be secondary to hypoxia (chronic lung disease), or primary in the case of polycythaemia rubra vera (a disorder of excess red blood cells).

- 30 An EPO antagonist will provide a therapy for polycythaemia.

A further example of a receptor: ligand binding is provided by the IL-6 activation of its cognate receptor. The current model for IL-6 activation of its cognate receptor stipulates that IL-6 binds to either soluble or membrane bound IL-6 receptor (IL-6R). The IL-6 /
5 IL-6R complex then recruits two molecules of gp130 and the tetramer signals through the dimerisation of the two gp130 molecules which possess cytoplasmic domains that associate with signalling molecules (Grotzinger *et al.*, 1999). In nature IL-6 and the IL-6R exist as separate molecules which possess high affinity binding sites for each other and the association with the signal transducing molecule gp130 occurs through covalent
10 linkage and the formation of disulfide bonds.

We have been studying receptor trafficking and binding protein production for two members of the cytokine receptor family; GH and leptin (9,16,20,21). These two hormones play a fundamental role in determining body composition in adults. Both
15 leptin and GH are important in regulating energy expenditure, appetite, and fat mass. The ability to manipulate the biological actions of leptin and GH will have important therapeutic outcomes for the treatment of both hormone excess and deficiency.

Using confocal microscopy and Frequency Resonance Energy Transfer (FRET) we have
20 shown that there is very rapid internalisation of GH receptor after ligand binding and that internalisation and signalling are independent functions (16). Our recent work shows that the GH antagonist, pegvisomant, despite having a mutated site 2, binds to a receptor dimer, is internalised in an identical fashion to GH, but does not trigger the conformational change required for signalling. We have demonstrated that the high dose
25 requirement of the antagonist relates to its internalisation and its differential binding to soluble and membrane bound receptor. The pegylated antagonist does not bind efficiently to membrane bound receptor and the non-pegylated antagonist is rapidly internalised and cleared.

We demonstrate that a truncated GHR, which lacks the cytoplasmic domain of the receptor, can act as a dominant negative antagonist of GH signalling, (Figure 5) (9,20). The truncated receptor is expressed at a high level on the cell surface as it lacks cytoplasmic domain essential for internalisation (16). The truncated receptor
5 heterodimerises with the full length receptor, blocks signalling as it lacks the cytoplasmic domain, and acts as a dominant negative because it is present in excess on the cell surface and prevents internalisation of the GH receptor complex.

There are two problems associated with using truncated receptors in the generation of
10 antagonists to GH. A truncated receptor in the membrane would have to be generated from within the cell. The GHR is also proteolytically cleaved and in time the majority of the truncated receptor would be lost into the circulation.

We link GH, through its C-terminus and a linker, to the N-terminus of the C-terminal
15 SD-100 domain of the GHR. By varying the length of the linker we define a molecule that has the flexibility to allow binding of GH through site 1 to full length receptor at the cell surface. The C-terminal SD-100 domain of the receptor will then rotate in to complete the trimeric structure GHR-GH-GHRtr where GHRtr is the C-terminal SD-100 domain. This complex neither signals nor internalises, and effectively antagonises GH
20 action. It has the additional advantages of low immunogenicity and low clearance as the majority of GH is cleared via the GHR (22).

We also demonstrate that the leptin receptor produces a soluble binding protein (21) as do many cytokine receptors (2), and the predominant peripheral form of the leptin
25 receptor is a truncated receptor similar to the truncated GHR (27,28). Our recent work has demonstrated that truncated leptin receptors can inhibit leptin signalling. The erythropoietin (EPO) receptor shares a very similar crystal structure to GHR and an EPO chimera with the C-terminal SD100 of the EPO receptor would function as an antagonist.

30

STATEMENTS OF INVENTION

According to the present invention there is provided a binding agent comprising a first
5 part capable of binding a ligand binding domain of a receptor linked to a second part
comprising a receptor binding domain wherein said binding agent modulates the activity
of the receptor.

In one embodiment of the invention, the binding agent antagonises the activity of the
10 receptor.

In an alternative embodiment of the invention, the binding agent agonises the activity of
the receptor.

15 Preferably the first part comprises a cytokine or the binding domain of a cytokine.

More preferably still the first part comprises a cytokine or the binding domain of a
cytokine selected from the following: growth hormone; leptin; erythropoietin; prolactin;
TNF, interleukins (IL), IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-9, IL-10, IL-11; the p35
20 subunit of IL-12, IL-13, IL-15; granulocyte colony stimulating factor (G-CSF);
granulocyte macrophage colony stimulating factor (GM-CSF); ciliary neurotrophic
factor (CNTF); cardiotrophin-1 (CT-1); leukemia inhibitory factor (LIF); oncostatin M
(OSM); interferon, IFN α and IFN γ .

25 Preferably the second part of the binding agent comprises at least part of the cognate
receptor of the cytokine or a part of an associated receptor.

Preferably the first part is GH.

Preferably the second part is one extracellular domain of GHR. More preferably the second part is the C-terminal SD-100 domain of GHR.

5 In an alternative embodiment the first part is IL-6 or a binding domain of IL-6 and the second part is a part of gp 130.

10 An embodiment of the invention exploits the high affinity of a cytokine for its receptor and the failure of truncated receptors to internalise to generate a specific receptor antagonist which is a chimera of the cytokine and its cognate receptor. The binding agent of the invention has the important advantage that binding of the cytokine to its receptor does not trigger internalisation of the receptor-cytokine complex. This means that dosage of the antagonist can be minimised.

15 In one embodiment of the invention, the binding agent is a fusion protein.

In an alternative embodiment of the invention, the first part is linked by a linker to the second part. The linker may be flexible.

20 The linker could be at any residue within the extracellular domain of the receptor which would allow growth hormone to flexibly bind with the free receptor at the cell surface. Where the first part is GH and the second part is one extracellular domain of GHR, the linkage may be made between any peptide residue in the GH and GHR. Preferably the linkage is made between a residue close to the C-terminus of the GH molecule and a residue close to the N-terminus of the GHR. More preferably the linkage is made
25 between a residue close to the C-terminus of the GH molecule and a residue close to the N-terminal of the N-terminal of the C-terminal SD-100. More preferably the linkage is made at any of residues 126-128 of the N-terminus of the C-terminal SD-100 of the GHR. In one embodiment of the invention, the linkage is made at residue 127 of the N-terminus of the C-terminal SD-100. Preferably the linker is a peptide.

30

It will be apparent to one skilled in the art that alternative linkers can be used to link first and second parts. By way of example and by no means of limitation, suitable linkers might be a nucleic acid (eg oligonucleotide); a peptide nucleic acid; a chemical crosslinker (eg polyoxyethylene).

5

The crystal structure of the GHR-GH-GHR complex reveals that the distance between the C-terminus of GH (residue 191) and N-terminus of the C-terminus SD-100 (residue 126-128) is 10A. This provides invaluable information with respect to linker design.

- 10 Preferably the linker is a polypeptide which comprises 5 to 30 amino acid residues. More preferably the linker comprises 10 to 20 amino acid residues.

More preferably the linker comprises at least one copy of the peptide:

- 15 Gly Gly Gly Gly Ser (hereinafter referred to as "Gly4Ser").

- In one embodiment of the invention the linker is 10 amino acids in length and comprises two copies of the Gly4Ser linker. In an alternative embodiment of the invention, the linker is 15 amino acids in length and comprises three copies of the Gly4Ser linker. In
20 yet an alternative embodiment, the linker is 20 amino acids in length and comprises four copies of the Gly4Ser linker.

- According to a further aspect of the invention there is provided a nucleic acid molecule comprising a nucleic acid sequence which encodes a binding agent according to the
25 invention selected from the group consisting of:

- i) the group comprising Figs 4, 5, 8, 9 and 21;
- ii) nucleic acids which hybridise to the sequences of (i) above and which have receptor modulating activity; and

- iii) nucleic acid sequences which are degenerate as a result of the genetic code to the sequences defined in (i) and (ii) above.

In a preferred embodiment of the invention said nucleic acid hybridises under stringent hybridisation conditions to the sequences represented in Figs 4,5,8,9, or 21.

- 5 Stringent hybridisation/washing conditions are well known in the art. For example, nucleic acid hybrids that are stable after washing in 0.1x SSC, 0.1% SDS at 60°C. It is well known in the art that optimal hybridisation conditions can be calculated if the sequence of the nucleic acid is known. For example, hybridisation conditions can be determined by the GC content of the nucleic acid subject to hybridisation. Please see
10 Sambrook et al (1989) Molecular Cloning; A Laboratory Approach. A common formula for calculating the stringency conditions required to achieve hybridisation between nucleic acid molecules of a specified homology is:

$$T_m = 81.5^\circ \text{C} + 16.6 \log [\text{Na}^+] + 0.41 [\% \text{G} + \text{C}] - 0.63 (\% \text{formamide}).$$

15

- Typically, hybridisation conditions uses 4 – 6 x SSPE (20x SSPE contains 175.3g NaCl, 88.2g $\text{NaH}_2\text{PO}_4 \cdot \text{H}_2\text{O}$ and 7.4g EDTA dissolved to 1 litre and the pH adjusted to 7.4); 5-10x Denhardt's solution (50x Denhardt's solution contains 5g Ficoll (type 400, Pharmacia), 5g polyvinylpyrrolidone and 5g bovine serum albumen/500ml; 100µg-
20 1.0mg/ml sonicated salmon/herring DNA; 0.1-1.0% sodium dodecyl sulphate; optionally 40-60% deionised formamide. Hybridisation temperature will vary depending on the GC content of the nucleic acid target sequence but will typically be between 42°- 65° C.

According to a further aspect of the invention there is provided a polypeptide which is encoded by a nucleic acid molecule according to the invention.

- 25 In a preferred embodiment of the invention the polypeptide so encoded is modified by deletion, addition or substitution of at least one amino acid residue. Ideally said modification enhances the antagonistic or agonistic effects of said polypeptide with respect to the inhibition or activation of receptor mediated cell signalling.

Alternatively, or preferably, said modification includes the use of modified amino acids in the production of recombinant or synthetic forms of polypeptides.

It will be apparent to one skilled in the art that modified amino acids include, by way of example and not by way of limitation, 4-hydroxyproline, 5-hydroxylysine, N⁶-acetyllysine, N⁶-methyllysine, N⁶,N⁶-dimethyllysine, N⁶,N⁶,N⁶-trimethyllysine, cyclohexylalanine, D-amino acids, ornithine. The incorporation of modified amino acids may confer advantageous properties on polypeptides comprising Fig 21. For example, the incorporation of modified amino acids may increase the affinity of the polypeptide for its binding site, or the modified amino acids may confer increased *in vivo* stability on the polypeptide thus allowing a decrease in the effective amount of therapeutic polypeptide administered to a patient.

According to a yet further aspect of the invention there is provided a vector including a DNA molecule encoding a binding agent according to any preceding aspect or embodiment of the invention.

15

In a preferred embodiment of the invention said vector is provided with means to recombinantly manufacture the binding agent of the invention.

In a preferred embodiment of the invention said vector is an expression vector adapted for prokaryotic gene expression.

20

Prokaryotic expression systems are well known in the art and comprise vectors adapted for high level constitutive and inducible expression. Inducible expression systems are particularly advantageous if the recombinant polypeptide is toxic to the bacterial cell. Induction of expression is tightly regulated by promoters responsive to various inducers (eg IPTG inducible). Bacterial cells can be grown to stationary phase before induction thereby reducing harmful effects of toxic polypeptides.

25

Additionally it is also well known in the art that certain polypeptides are difficult to manufacture recombinantly due, for example, to protein instability or problems of aggregation. It is well known that genetically modified bacterial strains are available which are mutated in genes (eg bacterial proteases) which facilitate the production of
5 native and recombinant bacterial polypeptides.

In a further preferred embodiment of the invention said vector is an expression vector adapted for eukaryotic gene expression.

- 10 Typically said adaptation includes, by example and not by way of limitation, the provision of transcription control sequences (promoter sequences) which mediate cell/tissue specific expression. These promoter sequences may be cell/tissue specific, inducible or constitutive.
- 15 Promoter is an art recognised term and, for the sake of clarity, includes the following features which are provided by example only, and not by way of limitation. Enhancer elements are *cis* acting nucleic acid sequences often found 5' to the transcription initiation site of a gene (enhancers can also be found 3' to a gene sequence or even located in intronic sequences and are therefore position independent). Enhancers
20 function to increase the rate of transcription of the gene to which the enhancer is linked. Enhancer activity is responsive to *trans* acting transcription factors (polypeptides) which have been shown to bind specifically to enhancer elements. The binding/activity of transcription factors (please see Eukaryotic Transcription Factors, by David S Latchman, Academic Press Ltd, San Diego) is responsive to a number of environmental
25 cues which include, by example and not by way of limitation, intermediary metabolites (eg glucose, lipids), environmental effectors (eg light, heat).

Promoter elements also include so called TATA box and RNA polymerase initiation selection (RIS) sequences which function to select a site of transcription initiation. These

sequences also bind polypeptides which function, *inter alia*, to facilitate transcription initiation selection by RNA polymerase.

Adaptations also include the provision of selectable markers
5 and autonomous replication sequences which both facilitate the maintenance of said vector in either the eukaryotic cell or prokaryotic host. Vectors which are maintained autonomously are referred to as episomal vectors.

Adaptations which facilitate the expression of vector encoded genes include the
10 provision of transcription termination/polyadenylation sequences. This also includes the provision of internal ribosome entry sites (IRES) which function to maximise expression of vector encoded genes arranged in bicistronic or multi-cistronic expression cassettes.

These adaptations are well known in the art. There is a significant amount of published
15 literature with respect to expression vector construction and recombinant DNA techniques in general. Please see, Sambrook et al (1989) Molecular Cloning: A Laboratory Manual, Cold Spring Harbour Laboratory, Cold Spring Harbour, NY and references therein; Marston, F (1987) DNA Cloning Techniques: A Practical Approach Vol III IRL Press, Oxford UK; DNA Cloning: F M Ausubel et al, Current Protocols in
20 Molecular Biology, John Wiley & Sons, Inc.(1994).

In yet a further aspect of the invention there is provided a method to prepare a binding agent polypeptide according to the invention comprising:

- 25 (i) growing a cell transformed or transfected with a vector or nucleic acid of the present invention in conditions conducive to the manufacture of said polypeptide;
and
(ii) purifying said polypeptide from said cell, or its growth environment.

In a preferred method of the invention said vector encodes, and thus said recombinant polypeptide is provided with, a secretion signal to facilitate purification of said binding agent polypeptide.

- 5 In yet a further aspect of the invention there is provided a cell transformed/transfected with the vector or nucleic acid according to the invention.

Preferably said cell eukaryotic and is selected from: fungal; insect (eg *Spodoptera frugiperda*); amphibian; plant; mammalian.

10

More preferably said cell is prokaryotic and is an *E. coli* cell.

- Preferably the binding agent of the present invention is used for the manufacture of a medicament for use in the treatment of acromegaly; gigantism; growth hormone
15 deficiency, Turners syndrome; renal failure; osteoporosis, diabetes mellitus, cancer; obesity; insulin resistance; hyperlipidaemia; hypertension (leptin chimera); anaemia; autoimmune and infectious disease; inflammatory disorders including rheumatoid arthritis.

- 20 According to a further aspect of the invention there is provided a pharmaceutical composition comprising the binding agent according to the invention. Preferably said pharmaceutical composition includes a carrier, excipient and/or a diluent.

- The invention also provides for a method of treating a human or animal subject
25 comprising administering an effective amount of the pharmaceutical composition/medicament to said subject.

- It will be apparent to one skilled in the art that the compositions/medicaments can be provided in the form of an oral or nasal spray, an aerosol, suspension, emulsion, and/or eye drop fluid. Alternatively the medicament may be provided in tablet form.
30 Alternative delivery means include inhalers or nebulisers.

Alternatively or preferably the medicament can be delivered by direct injection. It is also envisioned that the compositions/medicaments be delivered intravenously, intramuscularly, subcutaneously or topically. Further still, the compositions/medicaments may be taken orally or rectally.

- 5 The invention also provides a method of reduced renal clearance of a molecule comprising forming a binding agent according to any embodiment of the invention

An embodiment of the invention will now be described by example only and with reference to the following figures wherein;

10

Figure 1 represents a schematic diagram of (a) pTrcHis-TOPO and its derivatives; (b) pTrcHis-TOPO/GHstop; (c) pTrcHis-TOPO/Ghstop/GHR; (d) pTrcHis-TOPO/GH/link/GHR; (e) pTrcHis-TOPO/GH/link/flecGHRstop; f) pJONEXGHstop; pJONEXGHstoplink GHR;

15

Figure 2 represents the sequence of the cDNA of the 588bp PCR amplified GH fragment; (The 3'- NotI site and two stop codons are shown in bold and italics respectively)

- 20 Figure 3 represents the sequence of the cDNA of the 390bp PCR amplified GHR SD 100 fragment (The 5' EcoRI and 3' HindIII restriction sites are shown in bold and the 3' stop codons are shown in italics);

Figure 4 represents the nucleic acid sequence of the full length GHstopGHR SD100
25 construct;

Figure 5 represents the nucleic acid sequence of the full length GHlinkGHR construct (NotI, EcoRI and HindIII restriction sites are shown in bold and the two 3' stop codons are shown in italics);

30

Figure 6: represents the protein sequence of full length GHlinkGHR (340 amino acids);

Figure 7 represents the nucleic acid sequence of the 762bp PCR amplified full length extracellular domain of GHR (GHRflec) (the 5' **EcoRI** and **HindIII** sites are shown in bold and the two 3' stop codons are shown in italics);

5

Figure 8: represents the full length nucleic acid sequence of the GHlinkGHRflec construct (the **NotI**, **EcoRI** and **HindIII** site are shown in bold and the two 3' stop codons are shown in italics);

10 Figure 9: represents the nucleic acid sequence of the 1157bp PCR fragment, GHlinkGHR generated by oligonucleotides TrcRBSSacF and GHRA835H, (the **SacI**, **NotI**, **EcoRI** and **HindIII** sites are shown in bold, the new ribosome binding site is shown in bold and underlined and the start/stop codons are shown in italics);

15 Figure 10: represents the nucleic acid sequence of the 740bp PCR fragment, GHstop generated by nucleotides pTrcRBSSacI and TrcHindrev, (The **SacI**, **NotI**, **EcoRI** and **HindIII** sites are shown in bold, the new ribosome binding site is shown in bold and underlined and the start/stop codons are shown in italics);

20 Figure 11: represents the complete amino acid sequence of the GH/GHR receptor chimera (GH residues 1-191/ linker /GHR residues 127-246).

Figure 12A. represents the full length nucleic acid sequence of IL-6; Figure 12B represents the amino acid sequence of IL-6;

25

Figure 12 represents the full length nucleic acid sequence of gp130;

Figure 13 represents the amino acid sequence of the IL-6 /gp130 fusion polypeptide;

Figure 14 represents the nucleic acid sequence of the gp 130 domain 1 deletion (616-2112bp);

Figure 15 represents the nucleic acid sequence of gp130 domain 922-2112bp;

5

Figure 16 represents a western blot of induced proteins expressed by *E. coli* transformed with various vectors;

Figure 17 (a) is a graphical representation of reporter gene assays for Ghstop and GH link GHR; and (b) quantification of the data represented in (a); and

10

Figure 18 is a schematic representation of GH:GHR interaction and GH:GHR chimera interaction with GHR.

15 Figure 19 represents the *in vitro* agonist activity of the GH/GHR chimera.

Figure 20 shows the results of a bioassay comparing the induction of a Stat5 reporter (luciferase activity) by growth hormone (GH), a negative control (XL blue) and partially purified antagonist (Chimera 1A2)

20

Figure 21 represents the nucleotide sequence of the Chi 1A2 chimera.

Figure 22 represents the protein sequence of Chi 1A2 chimera (311 amino acids).

25 MATERIALS AND METHODS

Table 3 explains the nomenclature used to define the protein constructs.

Generation of GH:GHR Fusion Protein

Six constructs are cloned (including 3 different lengths of linker with or without the C241 of the GHR) into a C-terminal poly-His expression vector. Human GH is amplified

30

using high fidelity proof reading Pfu with convenient restriction sites to clone into the

vector. The C-terminus SD-100 GHR is similarly amplified and the linker constructed in the primer with convenient restriction sites to clone into the C-terminus of GH. The constructs are then fully sequenced.

- 5 From the crystal structure of the GHR-GH-GHR complex, the distance between the C-terminus of GH (residue 191) and N-terminus of the C-Terminus SD-100 GHR (residue 126-128) is 10 Å. Linkers between 10-20 residues are designed and three constructs made with linkers of either 10, 15 or 20 residues comprising of 2, 3 or 4 copies of the basic Gly₄Ser linker.

10

Protein Purification

- The constructs are expressed in *E. coli* (JM109) and the protein purified on Invitrogen Xpress System Nickel columns with a secondary purification step by ion exchange chromatography. Lipopolysaccharide should not interfere with the bioassay as this
15 requires a relatively short incubation in the cell culture system. If required the chimera antagonist is further purified using polymyxin B columns (Pierce).

Screening of Antagonist Activity

- An established bioassay is used to screen for antagonist activity (9). A permanent cell
20 line expressing the full length GHR is transiently transfected with a luciferase reporter that binds activated Stat5 (9). Twenty-four hours later the cells are stimulated with GH for 6 hours with or without antagonist. The cells are then lysed and luciferase activity measured (9).

Screening of Agonist Activity

- 25 A permanent cell line expressing the full length GHR is transiently transfected with a luciferase reporter that binds activated Stat5 (9). Twenty-four hours later the cells are stimulated with or without the GH/GHR chimera for 6 hours. The cells are then lysed and luciferase activity measured (9).

30

PCR OF PITUITARY GH FROM PITUITARY cDNA TO GENERATE GH_{stop}

Full-length human growth hormone was amplified from human pituitary cDNA using the Boehringer Expand High Fidelity PCR System. Each reaction consisted of: Primers GHS1-23 (forward) and GHA573not (reverse) 10µM each, 200µM dNTPs, 5µl Expand buffer plus magnesium chloride (1.5mM), and 0.6µl High fidelity enzyme mix in a total volume of 50µl.

10 Samples were as follows

1. Pituitary cDNA using GHS1-23 and GHA573not primers
2. Pituitary cDNA using actin specific primers
3. Control cDNA for actin
- 15 4. Water control.

PCR reaction master mix 1.

cDNA	2µl pituitary cDNA	2µl pituitary cDNA	2µl control cDNA	2µl water
Forward primer (10µM stock)	2µl GHS1-23	Actin primer 1µl	Actin primer 1µl	2µl GHS1-23
Reverse primer (10µM stock)	2µl <i>GHA573not</i>	Actin primer 1µl	Actin primer 1µl	2µl <i>GHA573not</i>
dNTP (10mM stock)	2µl	2µl	2µl	2µl
Sterile water	17µl	19µl	19µl	17µl

Master Mix 2 (per reaction)

10 x Expand High Fidelity buffer (plus magnesium) (5 μ l)

Sterile distilled water (19.4 μ l)

Expand High Fidelity Expand polymerase (0.6 μ l)

Added 25 μ l Master Mix 2 to Master mix 1 and overlaid with mineral oil.

PCR was carried out to the following method:

94°C: 2 minutes,

94°C: 30sec / 54°C: 1 minute / 72°C: 1 minute, for 30 cycles

72°C: 10min.

The 5'-nucleotide (GHS1-23) has sequence homology to the 5' end of the growth hormone gene and the 3'-nucleotide (GHA573not) contains a *Not* I site together with two stop codons. The PCR reaction produced a band of 588bp (see Figure 2) containing full-length human growth hormone. The fragment was then purified using the QIAquick PCR purification kit (Qiagen) and subsequently TOPO cloned into the pTrcHis-TOPO vector (Invitrogen, see Figure 1). Ligations were transformed in to *E. coli* TOPO one shot cells (Invitrogen) by the calcium chloride method. Plasmid mini preparations were produced from positive transformants and screened by restriction digest using *Pst*I/*Eco*RI. Clones with the correct insert size were then sequenced using vector specific primers supplied by invitrogen that bind 5' and 3' to the insert region (Xpress forward primer and pTrcHis reverse primer, see Table 1). This construct was named pTrcHisGHstop and was used as the template for subsequent cloning reactions.

Forward primer for Growth hormone primer "GHS1-23":

5'ttccaaccattcccttatccag 3'

Reverse primer *GHA573not*

5'ttatcagcggccgccgaagccacagctgccctccac 3'

PCR of GHR C-terminal SD100 domain from human liver cDNA

The GHR C-terminal SD100 domain (Figure 3) was amplified from human liver cDNA using the same PCR method as previously described, but using primers GHRS476 (forward) and GHRA835H (reverse), see table 1. The 5'-nucleotide contains an *EcoRI* site whilst the 3'-nucleotide contains two stop codons and a *HindIII* site.

The PCR reaction was carried out and cleaned up as described previously.

Samples were as follows:

1. liver cDNA using GHR476 and GHRA835H
2. liver cDNA using actin specific primers
3. Control cDNA
4. Water control.

PCR reaction: Master Mix 1

cDNA	1µl liver cDNA	1µl liver cDNA	1µl control cDNA	1µl Sterile water
Forward primer (10µM stock)	2µl <i>GHRS476</i>	Actin primer 1µl	Actin primer 1µl	2µl <i>GHRS476</i>
Reverse primer (10µM stock)	2µl <i>GHRA835H</i>	Actin primer 1µl	Actin primer 1µl	2µl <i>GHRA835H</i>

DNTP (10mM stock)	2 μ l	2 μ l	2 μ l	2 μ l
Sterile Water	18 μ l	19 μ l	19 μ l	17 μ l

Master Mix 2 (per reaction)

10 x Expand High Fidelity buffer (plus MgCl₂) (5 μ l)

Sterile distilled water (19.4 μ l)

High Fidelity Expand polymerase (0.6 μ l)

Added 25 μ l Master Mix 2 to Master mix 1 and overlaid with mineral oil.

Both vector, pTrcHisGHstop, and PCR product were subjected to a double digest using *Eco*RI and *Hind*III restriction enzymes (Promega). The PCR product was cleaned up using QIAquick PCR purification kit and the digested pTrcHisGHstop vector was separated by agarose gel electrophoresis and purified using the QIAquick gel extraction kit. The digested PCR fragment containing the C-terminal SD100 domain of GHR was then ligated to the above digested vector and transformed in to TOPO one shot cells (invitrogen) by the calcium chloride method. Ligations were transformed in to *E. coli* TOPO one shot cells (Invitrogen). Plasmid mini preparations were produced from positive transformants and screened by restriction digest using BamHI/*Eco*RI (Promega) and by PCR screening using GHS1-23 and GHRA835H primers. Clones with the correct insert size were then sequenced using pTrcHis reverse and GHseqF primers (see Table 1). This vector was called pTrcHisGHstopGHR and was used as the vehicle for the insertion of linker regions of varying lengths between GH and GHR in to the NotI/*Eco*RI sites. Figure 4 shows the full insert sequence for pTrcHisGHstopGHR.

This construct allows the insertion of a linker molecule in to the NotI/*Eco*RI sites between Ghstop and GHlinkGHR.

Insertion of linker regions

The initial linker was constructed composed of a 4x repeating sequence of four glycine residues and one serine residue (20 residues in total) by annealing oligonucleotides G4S4 (forward) and G4COM4 (reverse) see Table 1. The 5'-nucleotide contains a *NotI* site and the 3'-nucleotide contains an *EcoRI* site. The vector pTrcHisGHstopGHR, was double digested with *NotI* and *HindIII* restriction enzymes and cleaned up using the QIAquick clean up kit (Qiagen).

"G4S4"

5' ggccgcggtggcggaggtagtggcggcggaggtagcggcggcggaggttctggtggcggaggtccg 3'

"G4COMS4"

5' aattcggaacctccgccaccagaacctccgccaccgctacctccgccaccactacctccgccaccgc 3'

Preparation of linker insert:

Oligonucleotides G4S4 and G4COMS4 were resuspended in annealing buffer [10mM Tris-HCl, pH 7.5, 50mM NaCl, 1mM EDTA] to a final concentration 0.1pmol/μl. An equal volume of each oligonucleotide was then mixed and heated to 95°C for 2 minutes and then allowed to cool over a 1 hour period.

The oligonucleotide duplexes were then ligated to the *NotI*/*EcoRI* double digested vector pTrcHisGHstopGHR and transformed in to TOPO one shot cells (Invitrogen) by the calcium chloride method. Plasmid mini preparations were produced from positive transformants and screened by restriction digest using *NotI*/*EcoRI* and by PCR screening using GHS1-23 and GHRA835H primers. Clones with the correct insert size

were then sequenced using pTrcHis reverse primer and GHseqF (see Table 1). This vector was called pTrcHisGHlinkGHR (See figure 1).

The ligation process removes the 3' stop codons within the GHstop region thus allowing transcription of the full length GHlinkGHR.

The same strategy was employed in order to clone in the full length extracellular domain of GHR incorporating SD100 N and C-terminal domains.

Construction of full length extracellular domain of GHR (GHR_{flec})

The full length extracellular domain of GHR (SD100 N and C-terminal) was amplified using primers GHRS1ECOR and GHRA835H (see Table 1) following the same PCR protocol as described earlier for the generation of GHstop. The 5'-nucleotide (GHRS1ECOR) contains an EcoRI site and the 3'-nucleotide contains a HindIII site. The PCR reaction produced a band of 762bp (see Figure 7) containing full length extracellular GHR and purified using QIAquick PCR clean up kit (Qiagen). Both vector, pTrcHisGHlinkGHR and PCR product were subjected to a double restriction digest using EcoRI and HindIII restriction enzymes. The PCR product was cleaned up using QIAquick PCR clean up kits and the digested vector was separated by agarose gel electrophoresis and subsequently purified using the QIAquick gel extraction kit.

Both vector, pTrcHisGHlinkGHR, and PCR product were double digested with EcoRI and HindIII, and cleaned up using QIAquick clean up kits (Qiagen). The digested PCR fragment was then ligated in to the digested pTrcHisGHlinkGHR vector and transformed in to TOPO one shot cells (Invitrogen) by the calcium chloride method. Positive transformants were screened by restriction digest using EcoRI and HindIII and by PCR using primers GHRS1ECOR and GHRA835H. Clones with the correct sized insert were sequenced using GHseqF and the vector specific primer pTrcHis reverse. The new

construct was called pTrcHisGHlinkGHRflec. This can then be used as a template for any future linker inserts.

Cloning GHstop and GHlinkGHR into pJONEX4

pJONEX4 vector (See Figure1) was constructed in order to express inducible proteins that were potentially deleterious to the cell by placing them under the control of a strong repressor of transcription (cI857) and a heat inducible promoter (PL λ). The construction of pJONEX4 has been described elsewhere (Jon R. Sayers and Fritz Eckstein; Nucleic Acid Research, volume19, No15, p4127-4132, 1991).

The PL λ promoter region was cloned into pUC19 in the EcoRI site and engineered so that only one EcoRI site remained downstream of the promoter to produce pJONEX4. Genes wishing to be transcribed can be inserted into the SacI/HindIII region downstream of the PL λ promoter. This vector can be used to transform bacteria which specify a temperature sensitive lambda repressor (cI857), thus at low temperatures, below 30°C, transcription read through is prevented by the presence of the repressor protein. However, at higher temperatures (42°C) induction of protein expression proceeds. The main aim was to construct primers in order to PCR up the full length GHstop and GHlinkGHR from their parent vector pTrcHis-TOPO and subclone these fragments into the SacI/HindIII sites in pJONEX4.

5'-nucleotide, TrcRBSSacF contains an engineered SacI restriction site, a new ribosome binding site and the ATG start codon present in the pTrcHis-TOPO vector. Two 3'-nucleotides will be used to PCR GHstop and GHlinkGHR respectively from their parent vectors, pTrcHis. The 3'-nucleotide, TrcHindrev, contains a HindIII site and will be used to PCR the full length GHstop gene. The other nucleotide, GHRA835H has already been described, and will be used to PCR up GHlinkGHR (see Table 1).

TrcRBSSacIf:

5' gggaaa gagctc aaggagaaaataaa atg gggggttctcatcatcat 3'
SacI RBS START pTrc vector

TrcHindIIIrev:

5'gccaaagcttcgaattgaattcg 3'

PCR Method

96°C 2mins

94°C 30sec/54°C 1min/72°C 1min, for 30 cycles

72°C 10mins

PCR reaction; Master Mix 1

Plasmid (100ng total)	2µl pTrcHisGHstop	2µl pTrcHisGhlinkGHR	2µl water	2µl water
Forward primer (10mM stock)	2µl TrcRBSSacI	2µl TrcRBSSacI	2µl TrcRBSSacI	2µl TrcRBSSacI
Reverse primer (10mM stock)	2µl TrcHindrev	2µl GHRA835H	2µl TrcHindrev	2µl GHRA835H
DNTP (10mM stock)	2µl	2µl	2µl	2µl
Sterile water	17µl	17µl	17µl	17µl
Total volume	25µl	25µl	25µl	25µl

Master Mix 2 (per reaction)

5

Expand High Fidelity buffer (plus magnesium, 1.5mM final) (5µl)

Expand High Fidelity polymerase: (0.6µl)

Sterile water: (19.4µl)

- 10 Added 25µl Master Mix 2 to Master mix 1 and overlaid with mineral oil.

- Both PCR fragments and pJONEX4 vector were subjected to a double restriction digest using SacI/HindIII and purified using the QIAquick clean up kits (Qiagen). The digested PCR fragment was then ligated to the above digested vector and
- 15 transformed in to E. coli M72 (λ) cells by the method of electroporation. Plasmid mini preps were produced from positive transformants and screened by restriction digest using SacI/HindIII and by PCR using nucleotides TrcRBSSacI and TrcHindrev for Ghstop and TrcRBSSacI and GHRA835H for GHlinkGHR. Clones with the correct insert size were then sequenced using GHS1-23, GhseqF, Xpress forward and
- 20 GHA573not.

Cloning full length IL-6 and gp130 into pTZ18U/pTrcHis-TOPO/pJONEX4
vectors

5 The IL-6 / gp130 chimeras are provided in a variety of vectors. Cloning into pTZ18U will facilitate *in vitro* mutagenesis and the pJONEX and pTrcHis-TOPO vectors can be used to generate recombinant protein in *E. coli* which can be purified using Nickel columns.

10 Cloning is into pTrcHis using the TA cloning strategy devised for Ghstop/GHlinkGHR. The chimeras are then subcloned into the pJonex and pTZ18U system using the restriction sites BamHI/HindIII. This would maintain the upstream RBS and Hist6 tag in pJONEX and allow insertion into pTZ18U (they have the same multiple cloning site) for mutagenesis experiments.

15 The strategy is to TA clone in IL-6 (full length: see sequence below: Figure 1) with the 3'prime nucleotide containing a Not 1 site together with another restriction site: Sal1 (or Xho1). This Sal1 site will thus allow the cloning of the gp130 gene in to the Sal1/HindIII sites (HindIII being in 3'end of the pTrcHis vector). The linker can then be inserted into the Not1/Sal1 sites.

20

The construct once sequenced is subloned into the pJonex and pTZ18U vectors using BamHI/HindIII.

25 IL-6 and gp130 are amplified by PCR from IMAGE clones or cDNA from human lymphocytes.

The following primers will be used in TA cloning of the IL-6 sequence as represented in Figure 11 into pTrcHis.

30 Primers for cloning IL-6 into pTrcHis

Forward (5'nucleotide) PRIMER 1

5' gtacccccagg agaagattcc aaagatgtag 3' (31 mer with 15gc)

Reverse primer (3'nucleotide: NotI/SaII and Stop codons are shown in bold,
5 sequence shown in italics and underlined is insert sequence to keep sequence in
frame and as an overhang for NotI/SaII digestion and incorporates the stop
codons)

PRIMER 2

10

5' tgagggtcttcggcaaag g ggggccc **tgataa** gtcgac 3' (20 mer with 11gc)

5' cagctg **aatagt** cggcgccg g gtaaacggcttctcgggagt 3'

15 5' gtcgac **ttatca** ggggccc c catttgcgaagagccctca 3'(reverse nucleotide)

20

The next stage is to sub-clone the gp130 full length extracellular domain (322-2112bp; see Figure 12). Clone gp130 into the SalI/HindIII sites

5

Primers for cloning full length gp130 into pTrcHis-TOPO

Forward primer (5' nucleotide : SalI site shown in bold) PRIMER 3

10 5' gggaaa **gtcgac** gaacttcta gatccatgtg gtt3' (22 mer 9gc)

Reverse primer (HindIII and stop codons shown in bold) PRIMER 4

15 5' ccaaa gtttgct caaggagaaattgaa **tgataa aagctt** gggaaa 3'

5' aaaggg **ttcgaa aatagt** aagtaaagaggaac tcgttg aaacc3'

20 5' ttccc **aagctt ttatca** ttcaatttctcctg agcaaac ttgg3' (reverse nucleotide)

The step 3 is to ligate in the linker duplex that contain a 5'NotI site and a 3'SalI site.

25

LINKER DUPLEX

G4S4 Not/SalI (5' overhang for NotI and 3'overhang for SalI are shown in bold) PRIMER 7

30

5'ggccgcggtggcggaggtagtggtggcggaggtagcggtggcggaggttctggtggcggaggttcc g

G4S4rev/ Not/Sal 1(5' overhang for Not1 and SalI are shown in bold) PRIMER
8

5' **tcgac** ggaacctccgccaccagaacctccgccaccgctacctccgccaccactacctccgccacc **gc** 3'

5

This produces a full length construct: IL-6/link/gp130. The next step is to carry out cloning of domain deletions of gp130 into the SalI/HindIII sites.

Primers for cloning gp130 D1 deletion in to pTrcHIs-TOPO (SalI/HindIII sites)

10

forward primer (SalI site shown in bold) PRIMER 5

5' gggaaa **gtcgac** atttcaggcttgccctcca 3'

15

Reverse primer (HindIII and stop codons shown in bold) PRIMER 4

5' ccaaa gtttgct caaggagaaattgaa **tgataa aagctt** gggaaa 3'

20

5' aaaggg **ttcgaa aatagt** aagttaaagaggaac tcgttg aaacc3'

5' **ttccc aagctt ttatca** ttcaatttctccttg agcaaac ttgg3' (reverse nucleotide)

25

The next step is to clone in gp130 truncation up to 922bp (this deletes domains 1 and 2 from the extracellular region of gp130). Construct IL-6/link/gp130D1

30

Primers for cloning gp130 (922-2112bp fragment)

Forward primer (SalI site shown in bold) PRIMER 6

5' gggaaa gtcgac aatccgccacataatttat 3'

5 Reverse primer (HindIII and stop codons shown in bold) PRIMER 4

5' ccaaaa gttgct caaggagaaattgaa **tgataa aagctt** gggaaa 3'

5' aaaggg **ttcgaa aatagt** aagttaaagaggaac tcgtttg aaacc3'

10

5' ttcccc **aagctt ttatca** ttcaatttctccttg agcaaac ttggg3' (reverse nucleotide)

Preparation of Electrocompetant M72 (λ) cells

15

M72 (λ) cells were grown o/n in 50ml LB. 100ml of this o/n culture was then added to 900ml LB and grown at 30°C until OD600 was between 0.5-0.6. Cells were then harvested at 4000rpm, 20 min at room temperature using a Sorval RC-3B centrifuge. The pellet was resuspended and re-centrifuged at 4000rpm, 4°C, 20 minutes in gradually reducing volumes of sterile ice cold 10% (v/v) glycerol of 1000ml, 500ml, 250ml. The pellet was finally resuspended in 1000 μ l of 10% (v/v) glycerol, divided in to 100 μ l aliquots, flash frozen in liquid nitrogen and stored at -80°C.

20

Transformation of M72 cells.

25

Electrocompetant M72 (λ) cells were defrosted on ice and placed in to an electroporation cuvette (cell width of 0.1cm, Invitrogen) and electroporated at 1.8KV. Positive tranformants were selected for on LB plates supplemented with 100 μ g/ml ampicillin and grown at 30°C overnight.

30

Induction of Expression of constructs from pTrcHis-TOPO vectors

Transformed *E. coli* TOP 10 cells were grown overnight at 37°C with shaking at 200rpm in 10ml LB supplemented with ampicillin (100µg/ml final). The next day 5ml of the overnight was used to seed 250ml LB supplemented with ampicillin (100µg/ml final) and grown to an OD600 = 0.6. The culture was then induced with the addition of IPTG to a final concentration of 1mM and the cells grown for a further 5hrs. Induced cells were then harvested by centrifugation at 13000rpm, room temperature and the pellet either frozen or lysed.

Induction of Expression of constructs from pJONEX vectors

10

Transformed *E. coli* M72 (λ) cells were grown o/n at 30°C with shaking at 2000rpm in LB supplemented with ampicillin (100µg/ml). The next day the o/n culture was used to seed fresh LB and cells were grown until an OD600 of approximately 0.6 was reached. The temperature of the incubator was then adjusted to 42°C and an equal volume of pre-warmed media was added to bring the temperature of the culture up to 42°C. The cells were then grown at 42°C for a further 4-5hrs then harvested.

15

Purification of induced proteins by immobilised metal affinity chromatography (IMAC)

20

Induced cell pellets were resuspended in 20mM sodium phosphate buffer, 500mM sodium chloride, pH 7.8 and lysed by the addition of hen egg white lysozyme to a final concentration of 100µg/ml, and left on ice for 15 minutes. The cells suspension was then sonicated by applying three 10 second bursts on a medium intensity setting whilst holding on ice. Insoluble material was then removed by centrifugation at 40000 x g, 4°C for 20 minutes in a RC-3B centrifuge.

25

The cleared cell lysate was then applied to a Probond resin column (Invitrogen) pre-equilibrated with 20mM sodium phosphate buffer, 500mM NaCl, pH 7.8. The column washed with 20mM sodium phosphate buffer, 500mM sodium chloride, pH 7.8 buffer followed by washing with 20mM sodium phosphate buffer, 500mM

30

sodium chloride, pH 6.0. Bound protein was eluted by an increasing gradient of 50mM to 500mM imidazole made up in 20mM sodium phosphate buffer, 500mM sodium chloride, pH 6.0 buffer. 1ml fractions were collected and purification monitored by bradford protein assay and SDS-PAGE. Fractions containing proteins of interest were pooled and dialysed against 1000 volumes 20mM sodium phosphate buffer, pH 7.8, for 2, 4 and 6 hours respectively. Dialysed protein was then concentrated (if needed) using an Amicon Centriprep Y-10 column. Dialysed and concentrated samples were then either stored at 4°C or frozen or used directly in a bioassay for growth hormone activity.

10

Bioassay of rGH and purified growth hormone constructs

Hek293 cells were previously stably transfected with full-length human growth hormone receptor. Cells were routinely cultured in Dulbeccos MEM/Nutrient F12 medium supplemented with 10% Foetal calf serum, 1% penicillin/streptomycin and 1% L-glutamine. Cells used for the bioassay were first dissociated, counted, then plated at 2×10^5 cells/ml in growth medium in a 12 well plate and grown o/n at 37°C, 5% CO₂. The next day cells were placed in rich medium [2/3 Dulbeccos MEM/F12 nutrient medium, 1/3 Dulbeccos 4.5g/L-glucose, 10% Foetal calf serum, 1% penicillin/streptomycin and 1% L-glutamine] and incubated for 6 hours at 37°C. Transfection with reporter gene constructs was completed using the calcium phosphate transfection system (Life Technologies) according to the manufactures instructions. Cells were left overnight at 37°C, 5% CO₂. The next day cells were challenged with recombinant protein from 5-5000ng/ml, made up in starvation medium [Dulbeccos MEM/Nutrient F12 medium supplemented with 1% penicillin/streptomycin, 1% L-glutamine] supplemented with 100ng/μl dexamethasone. Where necessary recombinant wild type GH was mixed with purified GHstop or Chimeric protein in a competition assay. Cells were incubated at 37°C, 5% CO₂ for at least 5 hours before assaying for luciferase and β-galactosidase activity.

30

Luciferase/ β -galactosidase assay

The assays were performed according to the manufacturers instructions. Briefly media was aspirated from a 12 well plate and cells lysed with 150 μ l reporter lysis
5 buffer for 20 minutes at room temperature.

For the β -galactosidase assay 25 μ l of each lysate was added to duplicate wells of a 96 well plate and mixed with 75 μ l assay buffer. The plate was incubated at 37°C until a yellow coloration had developed at which point the plate was read at 420nm.

10 For the luciferase assay, 50 μ l of the remaining lysate was added to a luminometer cuvette to which was then added 50 μ l of luciferase substrate. The sample was mixed by vortexing for 10 seconds and fluorescence measured at 15 and 60 second intervals.

15 The final data was corrected for β -galactosidase expression by presenting results as a ratio of luciferase: β -galactosidase activity measured. Figure 17 shows data generated from a reporter gene assay using purified GH stop and GHlinkGHR.

Western blotting

20

Samples from purification's were routinely analysed for growth hormone expression by first separating samples by 12% (v/v) SDS-PAGE under either reducing or non-reducing conditions and transferring to PVDF membrane. The membrane was then blocked in 4%(w/v) milk protein in PBS, supplemented with 0.05% (v/v) Tween 20
25 (PBS-T). The membrane was then probed with anti-growth hormone (10A7, mouse IgG1) at 1/2000 dilution in 1% (w/v) milk protein in PBS-T. After brief washing the membrane was probed with Sheep anti mouse-HRP (Amersham) at 1/5000 dilution in 1%(w/v) milk protein in PBS-T. After extensive washing with PBS-T, specific protein bands were visualised using ECL western blot detection reagents
30 (Amersham). Figure 16 shows a western blot of induced proteins expressed either in the pTrcHis-TOPO of pJONEX vector systems.

Radioimmunoassay for growth hormone

The human growth hormone assay was performed using the NETRIA human growth hormone IRMA assay which uses a rabbit polyclonal and a labelled monoclonal antibody.

Table 1: RIA results for induced lysates of Ghstop and GHlinkGHR

Sample	Value (mU/L)
Ghstop induced cell lysate	583
GHlinkGHR induced cell lysate	504
Non-transfected cell lysate	42

Testing metabolic clearance rate in vivo

Sprague-Dawley rats are anaesthetised and cannulae implanted in femoral and jugular veins. Two days later GH or chimera is administered by intravenous or subcutaneous injection. Blood samples are collected via the femoral cannula and chimera levels measured by radio-immunoassay (see table 2). Pharmacokinetic parameters are estimated using available computer programs fitting hormone concentration against time.

Activation of GH signalling, measured as luciferase activity, by GH, negative control purification and Chi 1A2 (GH fused to GHR)

5 A number of chimeric constructs were made. The partially purified chimera was prepared from transformed XL blue *E. coli*. Protein from untransformed XL blue *E. coli* was purified over nickel columns and used as a negative control to detect any non-specific agonist or antagonist action. All purified proteins were stored in glycerol.

10 The negative control and Chimera 1A2 were incubated with and without GH.

Figure 19 shows results of bioassay comparing the induction of a Stat5 reporter (luciferase activity) by growth hormone (GH), negative control (XL blue), and partially purified antagonist (Chimera 1A2).

15

The graph shows the expected dose-response to GH. Incubation with negative control showed no induction of luciferase activity but at high concentration partially inhibited the bioassay (this may be an effect of the increased glycerol concentration). At 500 ng/ml Chimera 1 A2 appeared to completely block GH signalling.

20

References

- 25 1. Kishimoto, T., T. Taga, and S. Akira. 1994. Cytokine signal transduction. [Review] [92 refs]. *Cell* 76:253-262.
2. Muller-Newen, G., C. Kohne, and P.C. Heinrich. 1996. Soluble receptors for cytokines and growth factors. [Review] [58 refs]. *International Archives of Allergy & Immunology* 111:99-106.
- 30 3. Cunningham, B.C., M. Ultsch, A.M. de Vos, M.G. Mulkerrin, K.R. Clauser, and J.A. Wells. 1991. Dimerization of the extracellular domain of the

human growth hormone receptor by a single hormone molecule.
Science 254:821-825.

4. de Vos, A.M., M. Ultsch, and A.A. Kossiakoff. 1992. Human growth hormone and extracellular domain of its receptor: crystal structure of the complex. *Science* 255:306-312.
5. Sundstrom, M., T. Lundqvist, J. Rodin, L.B. Giebel, D. Milligan, and G. Norstedt. 1996. Crystal structure of an antagonist mutant of human growth hormone, G120R, in complex with its receptor at 2.9 Å resolution. *Journal of Biological Chemistry* 271:32197-32203.
- 10 6. Clackson, T., M.H. Ultsch, J.A. Wells, and A.M. de Vos. 1998. Structural and functional analysis of the 1:1 growth hormone:receptor complex reveals the molecular basis for receptor affinity. *Journal of Molecular Biology* 277:1111-1128.
- 15 7. Argetsinger, L.S. and C. Carter-Su. 1996. Growth hormone signalling mechanisms: involvement of the tyrosine kinase JAK2. [Review] [19 refs]. *Hormone Research* 45 Suppl 1:22-24.
8. Fuh, G., B.C. Cunningham, R. Fukunaga, S. Nagata, D.V. Goeddel, and J.A. Wells. 1992. Rational design of potent antagonists to the human growth hormone receptor. *Science* 256:1677-1680.
- 20 9. Ross, R.J., N. Esposito, X.Y. Shen, S. Von Laue, S.L. Chew, P.R. Dobson, M.C. Postel-Vinay, and J. Finidori. 1997. A short isoform of the human growth hormone receptor functions as a dominant negative inhibitor of the full-length receptor and generates large amounts of binding protein. *Molecular Endocrinology* 11:265-273.
- 25 10. Chen, C., R. Brinkworth, and M.J. Waters. 1997. The role of receptor dimerization domain residues in growth hormone signalling. *Journal of Biological Chemistry* 272:5133-5140.

11. Chen, W.Y., D.C. Wight, T.E. Wagner, and J.J. Kopchick. 1990. Expression of a mutated bovine growth hormone gene suppresses growth of transgenic mice. *Proceedings of the National Academy of Sciences of the United States of America* 87:5061-5065.
- 5 12. Chen, W.Y., D.C. Wight, B.V. Mehta, T.E. Wagner, and J.J. Kopchick. 1991. Glycine 119 of bovine growth hormone is critical for growth-promoting activity. *Molecular Endocrinology* 5:1845-1852.
13. Chen, W.Y., M.E. White, T.E. Wagner, and J.J. Kopchick. 1991. Functional antagonism between endogenous mouse growth hormone (GH) and a
10 GH analog results in dwarf transgenic mice. *Endocrinology* 129:1402-1408.
14. Chen, W.Y., N.Y. Chen, J. Yun, T.E. Wagner, and J.J. Kopchick. 1994. In vitro and in vivo studies of antagonistic effects of human growth hormone analogs [published erratum appears in J Biol Chem 1994 Aug
15 12;269(32):20806]. *Journal of Biological Chemistry* 269:15892-15897.
15. Mellado, M., J.M. Rodriguez-Frade, L. Kremer, C. von Kobbe, A.M. de Ana, I. Merida, and A. Martinez. 1997. Conformational changes required in the human growth hormone receptor for growth hormone signalling.
20 *Journal of Biological Chemistry* 272:9189-9196.
16. Maamra, M., J. Finidori, S. Von Laue, S. Simon, S. Justice, J. Webster, Dower, and R. Ross. 1999. Studies with a growth hormone antagonist and dual-fluorescent confocal microscopy demonstrate that the full-length human growth hormone receptor, but not the truncated isoform, is very rapidly
25 internalized independent of Jak2-Stat5 signalling. *Journal of Biological Chemistry* 274:14791-14798.
17. Cunningham, B.C., H.B. Lowman, J.A. Wells, R.G. Clark, K. Olson, and G. Fuh. 1998. Human growth hormone variants. *US Patent* #5 849:535

18. Thorner, M.O., C.J. Strasburger, Z. Wu, M. Straume, M. Bidlingmaier, S. Pezzoli, K. Zib, J.C. Scarlett, and W.F. Bennett. 1999. Growth hormone (GH) receptor blockade with a PEG-modified GH (B2036-PEG) lowers serum insulin-like growth factor-I but does not acutely stimulate serum GH. *Journal of Clinical Endocrinology & Metabolism* 84:2098-2103.
19. Ayling, R.M., R. Ross, P. Towner, S. Von Laue, J. Finidori, S. Moutoussamy, C.R. Buchanan, P.E. Clayton, and M.R. Norman. 1997. A dominant-negative mutation of the growth hormone receptor causes familial short stature [letter]. *Nature Genetics* 16:13-14.
20. Quinton, N.D., R.F. Smith, P.E. Clayton, M.S. Gill, S. Shalet, S.K. Justice, Simon, SA, S. Walters, M.C. Postel-Vinay, A.I.F. Blakemore, Ross, and RJM. 1999. Leptin binding activity changes with age: The link between leptin and puberty. *Journal of Clinical Endocrinology & Metabolism* 84:2336-2341.
21. Haffner, D., F. Schaefer, J. Girard, E. Ritz, and O. Mehls. 1994. Metabolic clearance of recombinant human growth hormone in health and chronic renal failure. *Journal of Clinical Investigation* 93:1163-1171.
22. Maini, R., E.W. St Clair, F. Breedveld, D. Furst, J. Kalden, M. Weisman, Smolen, P. Emery, G. Harriman, M. Feldmann, and P. Lipsky. 1999. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. *Lancet* 354:1932-1939.
23. Weinblatt, M.E., J.M. Kremer, A.D. Bankhurst, K.J. Bulpitt, R.M. Fleischmann, Fox, RI, C.G. Jackson, M. Lange, and D.J. Burge. 1999. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving

methotrexate [see comments]. *New England Journal of Medicine* 340:253-259.

24. Mohler, K.M., P.R. Sleath, J.N. Fitzner, D.P. Cerretti, M. Alderson, S.S. Kerwar, D.S. Torrance, C. Otten-Evans, T. Greenstreet, and K. Weerawarna. 1994. Protection against a lethal dose of endotoxin by an inhibitor of tumour necrosis factor processing. *Nature* 370:218-220.
25. Mohler, K.M., D.S. Torrance, C.A. Smith, R.G. Goodwin, K.E. Stremmler, V.P. Fung, H. Madani, and M.B. Widmer. 1993. Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. *Journal of Immunology* 151:1548-1561.
26. Ghilardi, N., S. Ziegler, A. Wiestner, R. Stoffel, M.H. Heim, and R.C. Skoda. 1996. Defective STAT signalling by the leptin receptor in diabetic mice. *Proceedings of the National Academy of Sciences of the United States of America* 93:6231-6235.
27. Tartaglia, L.A. 1997. The leptin receptor. [Review] [59 refs]. *Journal of Biological Chemistry* 272:6093-6096.
28. Tartaglia LA, Dembski M, Weng X et al. Identification and expression cloning of a leptin receptor, OB-R. *Cell* 1995; 83(7):1263-1271.
29. Livnah O, Stura EA, Middleton SA, Johnson DL, Jolliffe LK, Wilson IA. Crystallographic evidence for preformed dimers of erythropoietin receptor before ligand activation. *Science* 1999; 283(5404):987-990.
30. Remy I, Wilson IA, Michnick SW. Erythropoietin receptor activation by a ligand-induced conformation change. *Science* 1999; 283(5404):990-993.
31. BAUMANN, G. (1991) Growth hormone heterogeneity: genes, isohormones, variants, and binding proteins. *Endocrine Reviews*, 12, 424-449.

32. HAFFNER, D., SCHAEFER, F., GIRARD, J., RITZ, E. & MEHLS, O.
(1994) Metabolic clearance of recombinant human growth hormone in health
and chronic renal failure. *Journal of Clinical Investigation*, **93**, 1163-1171.
33. JOHNSON, V. & MAACK, T. (1977) Renal extraction, filtration, absorption,
5 and catabolism of growth hormone. *American Journal of Physiology*, **233**,
F185-F196
34. MANTZOROS, C.S. & FLIER, J.S. (2000) Editorial: leptin as a therapeutic
agent - trials and tribulations. *Journal of Clinical Endocrinology &
Metabolism*, **85**, 4000-4002.
- 10 35. PEEL, C.J., BAUMAN, D.E., GOREWIT, R.C. & SNIFFEN, C.J. (1981)
Effect of exogenous growth hormone on lactational performance in high
yielding dairy cows. *Journal of Nutrition*, **111**, 1662-1671.
36. SYED, S., SCHUYLER, P.D., KULCZYCKY, M. & SHEFFIELD, W.P.
(1997) Potent antithrombin activity and delayed clearance from the
15 circulation characterize recombinant hirudin genetically fused to albumin.
Blood, **89**, 3243-3252.

20

25

CLAIMS

1. A binding agent comprising a first part capable of binding a ligand binding domain of a receptor linked to a second part comprising a receptor binding domain
5 wherein said binding agent modulates the activity of the receptor.
2. A binding agent according to claim 1 wherein the binding agent antagonises the activity of the receptor.
- 10 3. A binding agent according to claim 1 wherein the binding agent agonises the activity of the receptor.
4. A binding agent according to any of claims 1 to 3 wherein the first part comprises a cytokine or the binding domain of a cytokine.
15
5. A binding agent according to claim 4 wherein the cytokine or the binding is selected from the following: growth hormone; leptin; erythropoietin; prolactin; TNF, interleukins (IL), IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-9, IL-10, IL-11; the p35 subunit of IL-12, IL-13, IL-15; granulocyte colony stimulating factor (G-CSF);
20 granulocyte macrophage colony stimulating factor (GM-CSF); ciliary neurotrophic factor (CNTF); cardiotrophin-1 (CT-1); leukemia inhibitory factor (LIF); oncostatin M (OSM); interferon, IFN α and IFN γ .
6. A binding agent according to claim 4 or claim 5 wherein the second part
25 comprises at least part of the cognate receptor of the cytokine or a part of an associated receptor.
7. A binding agent according to claim 5 or claim 6 wherein the first part is GH.
- 30 8. A binding agent according to any of claims 4 to 7 wherein the second part is one extracellular domain of GHR.

9. A binding agent according to claim 8 wherein the second part is the C-terminal SD-100 domain of GHR.
- 5 10. A binding agent according to claim 5 or claim 6 wherein the first part is IL-6 or a binding domain of IL-6 and the second part is a part of the IL-6 receptor or gp 130.
- 10 11. A binding agent according to any of claims 1 to 10 wherein the binding agent is a fusion protein.
12. A binding agent according to any of claims 1 to 11 wherein the first part is linked by a linker to the second part.
- 15 13. A binding agent according to claim 12 wherein the first part is GH and linkage is made between a residue close to the C-terminus of the GH molecule and a residue close to the N-terminus of the GHR.
- 20 14. A binding agent according to claim 13 wherein linkage is made between a residue close to the C-terminus of the GH molecule and a residue close to the N-terminal of the N-terminal of the C-terminal SD-100.
- 25 15. A binding agent according to claim 14 wherein linkage is made at any of residues 126-128 of the N-terminus of the C-terminal SD-100 of the GHR.
16. A binding agent according to claim 15 wherein linkage is made at residue 127 of the N-terminus of the C-terminal SD-100.
- 30 17. A binding agent according to any of claims 12 to 16 wherein the linker is a nucleic acid, a peptide nucleic acid or a chemical crosslinker.

18. A binding agent according to claim 17 wherein the linker is a peptide.
19. A binding agent according to claim 18 wherein the linker is a polypeptide which comprises 5 to 30 amino acid residues.
- 5 20. A binding agent according to claim 19 wherein the linker comprises 10 to 20 amino acid residues.
21. A binding agent according to any of claims 18 to 20 wherein the linker
10 comprises at least one copy of the peptide:

Gly Gly Gly Gly Ser (hereinafter referred to as "Gly4Ser").

22. A binding agent according to claim 21 wherein the linker comprises two
15 copies of the Gly4Ser linker.
23. A binding agent according to claim 21 wherein the linker comprises three copies of the Gly4Ser linker.
- 20 24. A binding agent according to claim 21 wherein the linker comprises four copies of the Gly4Ser linker.
25. A nucleic acid molecule comprising a nucleic acid sequence which encodes a binding agent according to any of Claims 1 to 24 selected from the group consisting
25 of:
- i) the group comprising Figures 4, 5, 8, 9 and 21
 - ii) nucleic acids which hybridise to the sequences of (i) above and which have receptor antagonising activity; and
 - iii) nucleic acid sequences which are degenerate as a result of the genetic
30 code to the sequences defined in (i) and (ii) above.

26. A nucleic acid according to Claim 25 which hybridises under stringent hybridisation conditions to the sequences represented in Figs 4, 5, 8, 9, or 21.
27. A polypeptide encoded by the nucleic acid according to claim 25 or 26.
28. A polypeptide according to claim 27 which is modified by deletion, addition or substitution of at least one amino acid residue.
29. A vector comprising the DNA molecule of any of claims 25 to 26.
30. A vector according to claim 29 wherein the vector is adapted for recombinant expression.
31. A vector according to claim 29 or claim 30 wherein said vector is an expression vector adapted for prokaryotic gene expression.
32. A vector according to claim 29 or claim 30 wherein said vector is an expression vector adapted for eukaryotic gene expression.
33. A vector according to any of claims 29 to 32 wherein said vector is provided with and therefore said binding agent includes a secretion signal to facilitate purification of said binding agent.
34. A cell transformed/transfected with the nucleic acid according to any of claims 25 to 26 or the vector according to any of claims 29 to 33.
35. A cell according to claim 34, wherein the cell is a eukaryotic cell.
36. A cell according to claim 35 wherein said cell is selected from the group consisting of: fungal cell; insect cell; amphibian cell; plant cell or mammalian cell.
37. A cell according to claim 34 wherein said cell is a prokaryotic cell.

38. A cell according to claim 37 wherein said cell is *Escherchia coli*.

39. A pharmaceutical composition comprising the binding agent according to any of claims 1-24.

5

40. A pharmaceutical composition according to claim 39 wherein said composition further comprises a carrier, excipient and/or a diluent.

41. The use of a binding agent according to any of claims 1-24 for the
10 manufacture of a medicament for use in the treatment of acromegaly; gigantism; GH deficiency; Turners syndrome; renal failure; osteoporosis; diabetes mellitus; cancer; obesity; insulin resistance; hyperlipidaemia; hypertension; anaemia; autoimmune and infectious disease; inflammatory disorders including rheumatoid arthritis (IL-6 chimera)

15

42. A method to prepare a binding agent polypeptide according to any of the preceding claims comprising:

- i) growing a cell transformed/transfected with a nucleic acid according to any of claims 25 to 26 or the vector of any of claims 29 to 33 in conditions
20 conducive to the manufacture of said polypeptide; and
- ii) purifying said polypeptide from said cell, or its growth environment.

43. A method of treating a human or animal subject comprising administering an effective amount of the agent according to any of claims 1-24 or the pharmaceutical
25 composition of any of claims 39 or 40 to said subject.

44. A nucleic acid comprising the nucleic acid sequence represented in Figure 4.

45. A nucleic acid comprising the nucleic acid sequence represented in Figure 5.
30

46. A nucleic acid comprising the nucleic acid sequence represented in Figure 8.

47. A nucleic acid comprising the nucleic acid sequence represented in Figure 9.

48. A nucleic acid comprising the nucleic acid sequence represented in Figure 21.

5

49. A polypeptide comprising the amino acid sequence of any of claims 6, 11 13
or 22.

50. A method for the manufacture of a binding agent according to any of claims
10 1-24 which provides a binding agent which has reduced systemic clearance
comprising linking a ligand binding domain of a receptor to a receptor binding
domain.

51. A method according to claim 50 wherein said binding agent is at least 70kDa.
15

52. A method according to claim 51 wherein said binding agent is between 70 and
80kDa.

53. A method according to claim 52 wherein said binding agent is greater than
20 80kDa.

25

30

Fig 1a




Fig 1b




Fig 1c




Fig 1d




Fig 1e




Fig 1f




Fig 1g




Figure 2:

ttccaaccattcccttatccaggcttttgacaacgctatgctccgcgccatcgtctgcaccagctggcctttgacacctaccag
gagtttgaagaagcctatatcccaaaggaacagaagtattcattcctgcagaacccccagacctccctctgtttctcagagtctat
tccgacacctccaacaggaggagaaacacaacagaaatccaacctagagctgctccgcatctccctgctgctcatccagtcgt
ggctggagcccgtgcagttcctcaggagtgtcttcgccaacagcctgggtacggcgccctctgacagcaacgtctatgacctc
ctaaaggacctagaggaaggcatccaacgctgatggggaggctggaagatggcagccccggactgggcagatcttcaa
gcagacctacagcaagttgcacaaaactcacacaacgatgacgcactactcaagaactacgggctgctctactgcttcagga
aggacatggacaaggtcgagacattcctgcgcacgtgagtgccgctctgtggagggcagctgtggcttcggcgccgctg
ataa

Figure 3:

gggaaagaattcgaaatagtgcaaccagatccaccattgccctcaactggactttactgaacgtcagtttaactgggattcatg
cagatatccaagtgagatgggaagcaccacgcaatgcagatattcagaaggatggatggttctggagtatgaacttcaataca
aagaagtaaatgaaactaaatggaaaatgatggaccctatattgacaacatcagttccagtgactcattgaaagtgataagga
atatgaagtgcgtgtgagatccaaacaacgaaactctggaaattatggcgagttcagtgaggtgctctatgtaacacttcctcag
atgagccaatttacatgtgaagaagatttctactgataaaagcttgggaaa

Figure 4**GHstop**

ttccaaccattcccttatccaggcttttgacaacgctatgctccgcgccatcgtctgcaccagctggcctttgacacctaccag
gagtttgaagaagcctatatcccaaaggaacagaagtattcattcctgcagaacccccagacctccctctgtttctcagagtctat
tccgacacctccaacaggaggaaacacacagaaatccaacctagagctgctccgcatctccctgctgctcatccagtcgt
ggctggagcccgtgcagttcctcaggagtgcttcgccaacagcctgggtgtacggcgcctctgacagcaacgtctatgacctc
ctaaaggacctagaggaaggcatccaacgctgatggggaggctggaagatggcagccccggactgggcagatcttcaa
gcagacctacagcaagttcgacacaaactcacacaacgatgacgcactactcaagaactacgggctgctctactgcttcagga
aggacatggacaaggctgagacattcctgcgcatcgtgcagtgccgctctgtggaggggcagctgtggcttcggcgccgctg
ataa

GHR

aagggcgaaatcgaaatagtgcaaccagatccaccattgccctcaactggactttactgaacgtcagtttaactgggattcatg
cagatatccaagtgagatgggaagcaccacgcaatgcagatattcagaaaggatggatgggtctggagtatgaacttcaataca
aagaagtaaatgaaactaaatggaaatgatggacctatattgacaacatcagttccagtgtactcattgaaagtggataagga
atatgaagtgcgtgtgagatccaacaacgaaactctggaaattatggcgagttcagtgaggtgctctatgtaacacttcctcag
atgagccaatttacatgtgaagaagatttctactgataaaagctt

Figure 5:**Growth Hormone:**

ttccaaccattcccttatccaggcttttgacaacgctatgctccgcgccatcgtctgcaccagctggccttgacacctaccag
gagtttgaagaagcctatatcccaaaggaaacagaagtattcctcctgcagaacccccagacctcctctgttctcagagtctat
tccgacacctccaacaggaggaaacacaacagaaatccaacctagagctgctccgcatctcctgctgctcatccagtcgt
ggctggagcccgtgcagttcctcaggagtgtcttcgccaacagcctgggtgtacggcgccctgacagcaacgtctatgacctc
ctaaaggacctagaggaaggcatccaaacgctgatggggaggctggaagatggcagccccggactgggcagatcttcaa
gcagacctacagcaagttcgacacaaactcacacaacgatgacgcactactcaagaactacgggctgctctactgcttcagga
aggacatggacaaggctcgagacattcctgcgcacgtgcagtgccgctctgtggagggcagctgtggctcggcgccgc

Linker

gggtggcggaggtagtgtgtggcggaggtagcggtggcggaggttctgtgtggcggaggttcc

Growth hormone receptor

gaattcgaaatagtgaaccagatccaccattgccctcaactggactttactgaacgtcagtttaactgggattcatgcagatat
ccaagtgagatgggaagcaccacgcaatgcagatattcagaaaggatggatgggtctggagtatgaactcaatacaaagaag
taaataaactaaatggaaaatgatggacctatattgacaacatcagttccagtgactcattgaaagtgataaggaatatgaa
gtgcgtgtgagatccaaacaacgaaactctggaattatggcgagttcagtgaggtgctctatgtaacacttcctcagatgagcc
aatattacatgtgaagaagatttctactgataaaagctt

Figure 6

fptiplsrlfdnaslrahrlhqlafdtyqefeeayipkeqkysflqnpqtslcfseiptpsnreetqqksnlellrisllliqswle
pvqflrsvfanslvygasdsnvdydllkdleegiqlmgrledgsprtggifkqtyskfdtnshddallknygllycfrkdmd
kvetflrivqcrsvegscgfggrggggsgggsgggsgggsgggsefeivqpdppialnwtllnvsltgihadiqvrweaprn
adiqkgwmvleyelqykevnetkwmmdpilttsvpvyslkvdkeyevrvrskqrnsgnygefsevlvltlpqmsqf
tceedfy**kl

Figure 7

gggaaagaattctttctggaagtgaggccacagcagctatccttagcagagcacctggagtctgaaagtgttaatccagg
cctaaagacaaattcttctaaggagcctaaattaccaagtgccgttcacctgagcgagagacttttcatgccactggacagat
gaggttcatcatggtacaaagaacctaggacccatacagctgttctataccagaaggaaactcaagaatggactcaagaatg
gaaagaatgccctgattatgttctgctgggaaaacagctgttactttaattcatcgtttacctccatctggataccttattgtatcaa
gctaactagcaatgggtggtacagtggatgaaaagtgttctctgttgatgaaatagtgaaccagatccaccattgccctcaact
ggactttactgaacgtcagtttaactgggattcatgcagatatccaagtgagatgggaagcaccacgcaatgcagatattcagaa
aggatggatggtctggagtatgaactcaatacaaagaagtaaataaaactaaatggaaaatgatggacctatattgacaaca
tcagttccagtgtactcattgaaagtggataaggaaatgaagtgcgtgtgagatccaacaacgaaactctggaaattatggcg
agttcagtgaggtgctctatgtaacacttctcagatgagccaatttacatgtgaagaagatttctactgataaaagctt

Figure 8**Growth hormone**

ttcccaaccattcccttatccaggcttttgacaacgctatgctccgcgccatcgtctgcaccagctggccttgacacctaccag
gagtttgaagaagcctatatcccaaaggaacagaagtattcattcctgcagaacccccagacctccctctgtttctcagagtctat
tccgacacctccaacagggaggaaacacaacagaaatccaacctagagctgctccgcatctccctgctgctcatccagtcgt
ggctggagcccgtgcagttcctcaggagtgcttcgccaacagcctgggtgtacggcgctctgacagcaacgtctatgacctc
ctaaaggacctagaggaaggcatccaacgctgatggggaggctggaagatggcagccccggactgggcagatcttcaa
gcagacctacagcaagttcgacacaaactcacacaacgatgacgcactactcaagaactacgggctgctctactgcttcagga
aggacatggacaaggctcgagacattcctgcgcatcgtgcagtgccgctctgtggagggcagctgtggcttcggcgccgc

Linker

ggtggcggaggtagtgtggtggcggaggtagcgtggcggaggttctggtggcggaggttcc

Growth hormone receptor :N-terminal SD100

Gaattcttttctggaagtgaggccacagcagctatccttagcagagcacctggagtctgcaaagtgttaatccaggcctaaa
gacaaattcttctaaggagcctaattcaccaagtgccgttcacctgagcgagagacttttcatgccactggacagatgaggttc
atcatggtacaaagaacctaggaccatacagctgttctataccagaaggaacactcaagaatggactcaagaatggaagaa
tgccctgattatgtttctgctggggaaaacagctgttactttaattcatcgtttacctccatctggataccttattgtatcaagctaacta
gcaatggtgtacagtggatgaaaagtgttctctgttgat

C-terminal SD100

Gaaatagtgaaccagatccaccattgccctcaactggactttactgaacgtcagtttaactgggattcatgcagatatccaag
tgagatgggaagcaccacgcaatgcagatattcagaaggatggatgggtctggagtatgaactcaatacaagaagtaaatg
aaactaaatggaaaatgatggaccctatattgacaacatcagttccagtggtactcattgaaagtggataaggaatatgaagtgcgt
gtgagatccaaacaacgaaactctggaaattatggcgagttcagtgaggtgctctatgtaacacttcctcagatgagccaatttac
atgtgaagaagatttctactgataaaagctt

Figure 9

Growth hormone

gggaaagagctcaaggagaaaataaaatgggggggttctcatcatcatcatcatcatggtaggtagcatgactggtaggaca
gcaaattgggtcgggatctgtacgacgatgacgataaggatccaacccctttccaaccattcccttaccaggcttttgacaacg
ctatgctccgcgcccatcgtctgcaccagctggcctttgacacctaccaggagttgaagaagcctatatcccaaaggaaacaga
agtattcattcctgcagaacccccagacctccctctgtttctcagagctattccgacacctccaacaggaggaaacacaaca
gaaatccaacctagagctgctccgcatctccctgctgctcatccagtcgtggctggagcccgtgcagttcctcaggagtgcttc
gccaacagcctggtgtacggcgctctgacagcaacgtctatgacctcctaaaggacctagaggaaggcatccaaacgtga
tggggagggtggaagatggcagccccggactgggcagatcttcaagcagacctacagcaagttcgacacaaactcacaca
acgatgacgcactactcaagaactacgggctgctctactgcttcaggaaggacatggacaaggctgagacattcctgcgcac
gtgcagtgccgctctgtggagggcagctgtggcttcggcgccgc

Linker

ggtggcggaggtagtggtggcggaggtagcggtggcggaggttctggtggcggaggttcc

Growth hormone receptor

gaattcgaaatagtgaaccagatccaccattgccctcaactggactttactgaacgtcagtttaactgggattcatgcagatat
ccaagtgagatgggaagcaccacgcaatgcagatattcagaaaggatggatggttctggagtagaacttaatacaagaag
taaatgaaactaaatggaaaatgatggacctatattgacaacatcagttccagtgactcattgaaagtgataaggaaatgaa
gtgcgtgtgagatccaaacaacgaaactctggaattatggcgaggttcagtgaggtgctctatgtaacattcctcagatgagcc
aatttacatgtgaagaagatttctactgataaaagcttgggaaa

Figure 10

gagctcaaggagaaaataaaatgggggggtctcatcatcatcatcatcatggtatggctagcatgactggggacagcaaat
gggtcgggatctgtacgacgatgacgataaggatccaaccctttccaaccattcccttatccaggcttttgacaacgctatgc
tccgcgcccacgtctgcaccagctggcctttgacacctaccaggagtttgaagaagcctatatcccaaagggaacagaagtatt
cattcctgcagaacccccagacctccctctgtttctcagagctattccgacacctccaacaggaggagaaacacaacagaaat
ccaacctagagctgctccgcatctccctgctgctcatccagctgtggctggagcccgtgcagttcctcaggagtgcttcgcaa
cagcctgggtgtacggcgcccttgacagcaacgtctatgacctcctaaaggacctagaggaaggcatccaacgctgatgggg
aggctggaagatggcagccccgggactgggcagatctcaagcagacctacagcaagttcgacacaaactcacacaacgat
gacgcactactcaagaactacgggctgctctactgcttcaggaaggacatggacaaggctgagacattcctgcgcacgtgca
gtgccgctctgtggagggcagctgtggcttcggcgccgctgataaaaggggcgaattcaattcgaagcttggc

Figure 11

A

gagctcaaggagaaaataaaaatggggggttctcatcatcatcatcatcatgggtatggctagcatgactgggtggacagcaa
atgggtcgggatctgtacgacgatgacgataaggatccaacccctttcccaaccattcccttatccaggcttttgacaacgctatgc
tccgcgcccatcgtctgcaccagctggcctttgacacctaccaggagtttgaagaagcctatatcccaaagggaacagaagtatt
cattcctgcagaacccccagacctcctctgtttctcagagtctattccgacacctccaacagggagggaacacacagaaat
ccaacctagagctgctccgcatctcctgctgctcatccagtcgtggctggagcccgtgcagttcctcaggagtgcttcgcca
cagcctgggtgtacggcgcccttgacagcaacgtctatgacctcctaaaggacctagaggaaggcatccaacgctgatgggg
aggctggaagatggcagccccggactgggcagatcttcaagcagacctacagcaagttcgacacaaactcacacaacgat
gacgcactactcaagaactacgggctgctctactgcttcaggaaggacatggacaaggtcgagacattcctgcgcacgtgca
gtgccgctctgtggagggcagctgtggcttcggcgccgcgtgataaaagggcggaattcaattcgaagcttggc

B

1 VPPGEDSK DVAAPHRQPL TSSERIDKQI RYILDGISAL RKETCNKSNM
51 CESSKEALAE>NNLNLPKMAE KDGCFOQSGFN EETCLVKIIT GLLEFEVYLE
101 YLQNRFESSE EQARAVQMST KVLIQFLQKK AKNLDAITTP DPTTNASLLT
151 KLQANQWLQ DMTHLILRS FKEFLQSSLR ALRQMGR** VDKG

Figure 12

gaacttcta gatccatgtg gttatatcag tcttgaatct ccagttgtac aacttcattc taatttcaact gcagtttgtg
 tgctaaagga aaaatgtatg gattattttc atgtaaagtc taattacatt gtctggaaaa caaaccattt tactatttct
 aaggagcaat atactatcat aaacagaaca gcatccagtg tcacctttac agatatagct tcattaaata ttacagtcac
 ttgaacatt cttacattcg gacagcttga acagaatgtt tatggaatca caataatttc aggcttgcct ccagaaaaac
 ctaaaaattt gagttgcatt gtgaacgagg ggaagaaaaat gaggtgtgag tgggatggtg gaagggaac
 acacttgag acaaacttca ctttaaaatc tgaatgggca acacacaagt ttctgtattg caaagcaaaa cgtgacaccc
 ccacctcatg cactgttgat tattctactg tgtatttctg caacattgaa gtctgggtag aagcagagaa tgccttggg
 aaggttacat cagatcatat caatttcat cctgtatata aagtgaagcc caatccgcca cataatttat cagtgatcaa
 ctacagaggaa ctgtctagta tcttaaaatt gacatggacc aaccaagta ttaagagtgt tataatacta
 aaatataaca ttcaatatag gaccaaagat gcctcaactt ggagccagat tctcctgaa gacacagcat ccacccgatc
 ttatttcaact gtccaagacc ttaaaccttt tacagaatat gtgttagga ttctgtgtat gaaggaagat ggtaaggat
 actggagtga ctggagtga gaagcaagt ggatcaccta tgaagataga ccatctaaag caccaagttt ctgtataaa
 atagatccat cccatactca aggctacaga actgtacaac tctgtggaa gacattgcct cctttgaag ccaatggaaa
 aatcttggat tatgaagtga ctctcacaag atggaaatca catttcaaaa attacacagt taatgccaca aaactgacag
 taaatctcac aaatgatcgc tatctagcaa cctaacagt aagaaatctt gttggcaaat cagatgcagc tgttttaact
 atccctgcct gtgacttca agctactcac cctgtaatgg atcttaagc attcccaaa gataacatgc ttgggtgga
 atggactact ccaagggaat ctgtaaagaa atatatactt gagggtgtg tttatcaga taaagacccc tttatcacag
 actggcaaca agaagatggg accgtgcatc gcacctattt aagagggaac ttacagaga gcaaatgcta ttgataaca
 gttactccag tatatgtga tggaccagga agccctgaat ccataaaggc atacctaaa caagctccac ctccaaagg
 acctactgtt cggacaaaaa aagtagggaa aaacgaagct gtcttagagt gggaccaact tctgttgat gttcagaatg
 gatttatcag aaattatact atattttata gaacctcat tggaaatgaa actgctgtga atgtggattc ttccacaca
 gaatatatcat tgtcctctt gactagtac acattgtaca tggtagaat ggcagcatc acagatgaag gtgggaagga
 tggccagaa ttactttta ctacccaaa gtttgcct caa ggagaaattg aa

Figure 13

1 VPPGEDSKDV AAPHRQPLTS SERIDKQIRY ILDGISALRK ETCNKS NMCE
51 SSKEALAENN LNLPKMAEKD GCFQSGFNEE TCLVKIITGL LEFEVYLEYL
101 QNRFESSEEQ ARAVQMSTKV LIQFLQKKAK NLDAITTPDP TTNASLLTKL
151 QAQNQWLQDM TTHLILRSFK EFLQSSLRAL RQMGGRGGGG SGGGSGGGG
201 SGGGGSVDEL LDPCGYISPE SPVQLHSNF TAVCVLKEKC MDYFHV NANY
251 IVWKTNHFTI PKEQYTIINR TASSVTFTDI ASLNIQLTCN ILTFGQLEQN
301 VYGITIISGL PPEKPKNLSC IVNEGK KMRC EWDGGRETHL ETNFTLKSEW
351 ATHKFADCKA KRDTPTSCTV DYSTVYFVNI EVWVEAENAL GKVTSDHINF
401 DPVYKVKPNP PHNLVINSE ELSSILKLTW TNPSIKSVII LKYNIQYRTK
451 DASTWSQIPP EDTASTRSSF TVQDLKPFTE YVFRIRCME DGKGYWSDWS
501 EEASGITYED RPSKAPSEFY KIDPSHTQGY RTVQLVWCTL PPFEANGKIL
551 DYEVTLTRWK SHLQNYTVNA TKLTVNLTND RYLATLTVRN LVGKS DAAVL
601 TIPACDFQAT HPVMDLKAFP KDNMLWVEWT TPRESVKKYI LEWCVLSDKA
651 PCITDWQOED GTVHRTYLRG NLAESKCYLI TVTPVYADGP GSPESIKAYL
701 KQAPPSKGPT VRTKKVGKNE AVLEWDQLPV DVQNGFIRNY TIFYRTIIGN
751 ETAVNV DSSH TEYTLSSLTS DTLYMVRMAA YTDEGGK DGP EFTFTTPKFA
801 QGEIE**KL


Figure 14

attcaggcttgctccagaaaaacctaataattgagttgcattgtgaacgaggggaagaaaatgaggtgtgagtgggatggt
ggaagggaacacacttgagacaaacttcactttaaatctgaatgggcaacacacaagtttgctgattgcaaagcaaacgt
gacacccccacctcatgcactgttgattattctactgtgtattttgtcaacattgaagctgggtagaagcagagaatgcccttggg
aaggttacatcagatcatatcaatttgcctgtatataaagtgaagccaatccgccacataatttatcagtgatcaactcagag
gaactgtctagtatcttaaaattgacatggaccaaccaagtattaagagtggtataataactaaaataacattcaatataggacca
aagatgcctcaacttgagccagattcctcctgaagacacagcatccaccgatcttcattcactgtccaagaccttaaacctttt
acagaatatgtgttaggattcgtgtatgaaggaagatggtaagggatactggagtgactggagtgagaagcaagtgggat
cacctatgaagatagaccatctaaagcaccaagtttctgggtataaaatagatccatccatactcaaggctacagaactgtacaa
ctcgtgtggaagacattgcctcctttgaagccaatggaaaaatcttgattatgaagtactctcacaagatggaaatcacattta
caaaattacacagttaatgccacaaaactgacagtaaatctcacaatgatcgtatctagcaaccctaacagtaagaaatcttgt
tggcaaatcagatgcagctgttttaactatccctgcctgtgactttcaagctactcacctgtaatggatcttaagcattcccaaa
gataacatgctttgggtggaatggactactccaagggaatctgtaagaaatatacttgagtgggtgtgtgttatcagataaagc
accctgtatcacagactggcaacaagaagatggtagcgtgcacctatttaagagggaacttagcagagagcaaatgct
atttgataacagttactccagtatatgtgtgatggaccaggaagccctgaatccataaaggcataccttaacaagctccacctcc
aaaggacctactgttcggacaaaaaaagtagggaaaaacgaagctgtcttagagtgaggaccaactcctgttgatgttcagaat
ggatttatcagaaattatactatattttagaaccatcattggaaatgaaactgctgtgaatgtggattctccacacagaatatac
attgtcctctttgactagtacacattgtacatggtacgaatggcagcatacacagatgaaggtgggaaggatgggtccagaattc
acttttactaccccaaagtttgc tcaaggagaaattgaa

Figure 15

aatccgccacataatttatcagtgatcaactcagaggaactgtctagtatcttaaaattgacatggaccaaccaagtattaagagt
gttataatactaaaatataacattcaatataaggaccaaagatgcctcaactggagccagattcctcctgaagacacagcatccac
ccgatcttcattcactgtccaagaccttaaaccttttacagaatatgtgttaggattcgtgtatgaaggaagatgtaaggata
ctggagtgactggagtgaagaagcaagtgggatcacctatgaagatagaccatctaaagcaccaagtttctgtataaaataga
tccatcccatactcaaggctacagaactgtacaactcgtgtggaagacattgcctcctttgaagccaatggaaaaatcttgatt
atgaagtgactctcacaagatggaaatcacattacaaaattacacagttaatgccacaaaactgacagtaaatttcacaaatgat
cgctatctagcaaccctaacagtaagaaatctgttggaatcagatgcagctgtttaactatccctgcctgtgactttcaagcta
ctcaccctgtaatggatcttaaagcattcccaaagataaacatgctttgggtggaatggactactccaagggaatctgtaagaa
atatatacttgagtgggtgtgttatcagataaagcacctgtatcacagactggcaacaagaagatggtaccgtgcatcgacc
tatttaagagggaacttagcagagagcaaatgctatttgataacagttactccagtatatgctgatggaccaggaagccctgaat
ccataaaggcataccttaacaagctccacctccaaaggacctactgttcggacaaaaaagtagggaaaaacgaagctgtc
ttagagtgggaccaacttcctgttgatgttcagaatggatttatcagaaattatactatattttatagaaccatcattgaaatgaac
tgctgtgaatgtggattctccacacagaatatacattgtcctcttgactagtacacattgtacatggtacgaatggcagcatac
acagatgaaggtgggaaggatggtccagaattcattttactaccccaaagtttgctcaaggagaaattgaa

FIGURE 16.

**Sample description:**

GHlinkGHRflec: pTrcHisGHlinkGHRflec, contains full length extracellular domain of growth hormone receptor (IPTG induced).

GHlinkGHR: pTrcHisGhlinkGHR, contains only C-terminal SD100 of growth hormone receptor (IPTG induced)

GH: pTrcHisGHstop, contains full length growth hormone (IPTG induced)

GHi: pJonexGHstop, contains full length GH (heat induced)

rGH: purified recombinant human growth hormone

GHlinkGHRI: pJonexGHlinkGHR, contains full length GhlinkGHR (heat induced)

Figure 17A: Reporter gene assay for His-tag purified Ghstop and GHlinkGHR.




Figure 17B: Reporter gene assay: Table of results obtained for His-tag purified Ghstop and GHlinkGHR

Sample	Activity ratio	Standard error	Fold induction
Non stimulated	4.54	0.3	1
rGH 50	53.73	1.46	11.8
rGH 100	82.08	3.3	18.1
rGH 200	93.65	5.57	20.6
rGH 500	108.54	5.02	23.9
rGH 5000	76.93	13.37	16.9
Non stimulated	4.61	0.6	1
rGh 50	98.61	7.9	21.4
Ghstop 100	5.36	0.05	1.2
Ghstop 500	8.44	1.3	1.8
Ghstop 1000	45.92	0.56	10
Ghstop 5000	71.24	6.89	15.4
Non stimulated	4.38	0.91	1
rGH 100	92.76	0.92	21.1
Chi 500	8.12	2.82	1.85
Chi 1000	15.18	16	3.46
Chi 5000			

25/28

Figure 18:





Figure 19: Bioassay of GH showing dose response for genotropin and GHlinkGHR






Figure 21: The chimera 1A2 was generated using the phagemid method to remove the linker sequence from GHlinkGHR and generate a fusion protein of the C-terminus of growth hormone directly the N-terminus of the GHR SD100. The DNA sequence is given below (GH in bold and GHR SD100 in italics)

ttcccaaccattcccttattccaggctttttgacaacgctatgctccgcgcccatgtctgcaaccagctggcctttgacacctaccaggagtttga
agaagcctatacccaagggaacagaagtattcattctgcagaacccccagacctccctctgtttctcagagtctattccgacacctccaa
cagggaggaaacacaacagaaatccaacctagagctgctccgcatctccctgctgctcatccagctggtggaggagcccgctgagttcctca
ggagtgtcttcgccaacagcctgggtgaeggcgctctgacagcaacgtctatgacctcctaaggacctagaggaaggcatccaaacgct
gatggggagggtggaagatggcagccccggactgggcagatcttcaagcagacctacagcaagttcgacacaaactcacacaacgatg
acgcactactcaagaactacgggctgctctactgcttcaggaaggacatggacaaggctcgagacattcctgcgcatctgctgagtcgctct
gtggaggggcagctgtggttcgaaatagtgcacaccagatccacccattgccctcaactggactttactgaacgtcagtttaactgggattcatgc
agatatccaagtgagatgggaagcaccacgcaatgcagatattcagaaggatggatgggtctggagatgaactcaatacaagaagtaa
atgaaactaaatggaaatgatggacctatattgacaacatcagttccagtgactcattgaaagtgagataagggaatggaagtgcgtgtgaga
tccaaacaacgaaactctggaaattatggcgagttcagtgagggtgctctatgtaacacttcctcagatgagccaattacatgtaagaagattct
actgataaaagctt

Figure 22: Protein sequence of Chi 1A2 (311 amino acids)

Fptiplsrldnaslrhrlhqlafdyqefeeayipkeqkysflqnpqtslcsesiptpsnreetqqksnlellrisllliqswlepqvflrsv
fanslvygasdsnvdydlldleegiqlmrgledgsprtgqifkqtyskfdtnshnddallknyglycfrkdmkvctflrivqcrsveg
scgfeivqpdppialnwillnvtlgihadigvrweaprnadiqkgwmvleyelqykevneltkwkmmdpilttsvpvyslkvdkeyevrvrskq
rnsngmygefsevhvylpqmsqficeedfy**kl

This Page Blank (uspto)



For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

INTERNATIONAL SEARCH REPORT

In onal Application No

F. 1, 3B 01/02645

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12N15/12 C12N15/18 C12N15/24 C12N15/62 C07K14/54
C07K14/61 C07K14/715 C07K14/72 A61K38/17

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N C07K A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

BIOSIS, EPO-Internal, SEQUENCE SEARCH, MEDLINE, PAJ, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 97 32891 A (ANGEWANDTE GENTECHNOLOGIE SYST ; ROSE JOHN STEFAN (DE)) 12 September 1997 (1997-09-12) page 6 figures 1,2	1-6, 10-12, 17-23, 50-53
X	WO 99 02552 A (KOLLET ORIT ; LAPIDOT TSVEE (IL); CHEBATH JUDITH (IL); REVEL MICHEL) 21 January 1999 (1999-01-21) page 7, line 16 -page 8 page 28 -page 30; example 1 figure 11 page 54 -page 60; claims 1-37 page 32; example 2 -/-	1-6, 10-12, 17-20, 50-53

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *A* document member of the same patent family

Date of the actual completion of the international search

7 February 2002

Date of mailing of the international search report

21 02 2002

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3018

Authorized officer

Blanco Urgoitl, B

INTERNATIONAL SEARCH REPORT

Int. Patent Application No

PCT/GB 01/02645

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 4 857 637 A (MARTIN JR DAVID W ET AL) 15 August 1989 (1989-08-15) figure 2	44-47
X	WO 86 05804 A (NORDISK GENTOFTE) 9 October 1986 (1986-10-09) figure 1	44-46
X	WO 90 05185 A (UNIV LIEGE) 17 May 1990 (1990-05-17) figure 3	44-46
A	ROSS R J M ET AL: "A short isoform of the human growth hormone receptor functions as a dominant negative inhibitor of the full-length receptor and generates large amounts of binding protein." MOLECULAR ENDOCRINOLOGY, vol. 11, no. 3, 1997, pages 265-273, XP002181691 ISSN: 0888-8809 cited in the application	
A	WO 00 18932 A (STAHL NEIL ;REGENERON PHARMA (US); YANCOPOULOS GEORGE D (US)) 6 April 2000 (2000-04-06)	
A	WO 92 21029 A (GENENTECH INC) 26 November 1992 (1992-11-26)	
A	EP 0 950 710 A (JAPAN CHEM RES) 20 October 1999 (1999-10-20)	
A	MORAN P ET AL: "A NONFUNCTIONAL SEQUENCE CONVERTED TO A SIGNAL FOR GLYCOPHOSPHATIDYLINOSITOL MEMBRANE ANCHOR ATTACHMENT" JOURNAL OF CELL BIOLOGY, vol. 115, no. 2, 1991, pages 329-336, XP001031102 ISSN: 0021-9525	
A	YIYING ZHANG ET AL: "POSITIONAL CLONING OF THE MOUSE OBESE GENE AND ITS HUMAN HOMOLOGUE" NATURE, MACMILLAN JOURNALS LTD. LONDON, GB, vol. 372, no. 6505, 1 December 1994 (1994-12-01), pages 425-432, XP000602062 ISSN: 0028-0836	

-/-

Form PCT/ISA/210 (continuation of second sheet) (July 1992)

INTERNATIONAL SEARCH REPORT

International Application No
PCT/GB 01/02645

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.1
A	TARTAGLIA L A ET AL: "IDENTIFICATION AND EXPRESSION CLONING OF A LEPTIN RECEPTOR, OB-R" CELL, CELL PRESS, CAMBRIDGE, NA, US, vol. 83, no. 7, 29 December 1995 (1995-12-29), pages 1263-1271, XP000602068 ISSN: 0092-8674	
A	EP 0 741 187 A (HOFFMANN LA ROCHE) 6 November 1996 (1996-11-06)	
A	HIBI M ET AL: "MOLECULAR CLONING AND EXPRESSION OF AN IL-6 SIGNAL TRANSDUCER, GP130" CELL, CELL PRESS, CAMBRIDGE, NA, US, vol. 63, 21 December 1990 (1990-12-21), pages 1149-1157, XP002931740 ISSN: 0092-8674	

Form PCT/ISA210 (continuation of second sheet) (July 1992)

INTERNATIONAL SEARCH REPORT

ational application No.
PCT/GB 01/02645

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Although claim 43 is directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this International application, as follows:

see additional sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☒ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
(1-4, 7-10, 13-16, 25-38, 42, 44-48) complete; (5, 6, 11, 12, 17-24, 39-41, 43, 49-53) partially
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☒ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: (1-4,7-9,13-16,25-38,42,44-48) complete; (5,6,11,12,17-24,39-41,43,49-53) partially

A binding agent comprising the binding domain of a ligand linked to a receptor binding domain, wherein the binding agent agonises or antagonises the activity of the receptor; said binding agent comprising at least part of a cytokine; said binding agent comprising GH and the extracellular domain of GHR or the C-terminal SD-100 domain of GHR; said binding agent being a fusion protein; said binding agent wherein both domains are linked by a linker; said binding agent wherein the linkage is made close to the C-terminus of GH and the N-terminus of GHR, or of the C-terminal SD-100 domain of GHR; wherein the linker comprises at least one copy of the peptide "Gly4Ser"; a nucleic acid comprising figures 4,5,8,9 or 21, derived polypeptides, vectors, host cells, pharmaceutical compositions, uses in the manufacture of medicaments, methods of preparation, methods of treatment.

2. Claims: (5,6,11,12,17-24,39-41,43,49-53) partially

A binding agent comprising at least the binding domain of leptin linked to the binding domain of an associated receptor, wherein the binding agent agonises or antagonises the activity of the receptor; said binding agent being a fusion protein; said binding agent wherein both domains are linked by a linker; said linker comprises at least one copy of the peptide "Gly4Ser"; pharmaceutical compositions, uses in the manufacture of medicaments, and methods of preparation.

3. Claims: (5,6,11,12,17-24,39-41,43,49-53) partially

A binding agent comprising at least the binding domain of erythropoietin linked to the binding domain of an associated receptor, wherein the binding agent agonises or antagonises the activity of the receptor; said binding agent being a fusion protein; said binding agent wherein both domains are linked by a linker; said linker comprises at least one copy of the peptide "Gly4Ser"; pharmaceutical compositions, uses in the manufacture of medicaments, and methods of preparation.

4. Claims: (5,6,11,12,17-24,39-41,43,49-53) partially

A binding agent comprising at least the binding domain of prolactin linked to the binding domain of an associated

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

receptor, wherein the binding agent agonises or antagonises the activity of the receptor; said binding agent being a fusion protein; said binding agent wherein both domains are linked by a linker; said linker comprises at least one copy of the peptide "Gly4Ser"; pharmaceutical compositions, uses in the manufacture of medicaments, and methods of preparation.

5. Claims: (5,6,11,12,17-24,39-41,43,49-53) partially

A binding agent comprising at least the binding domain of TNF linked to the binding domain of an associated receptor, wherein the binding agent agonises or antagonises the activity of the receptor; said binding agent being a fusion protein; said binding agent wherein both domains are linked by a linker; said linker comprises at least one copy of the peptide "Gly4Ser"; pharmaceutical compositions, uses in the manufacture of medicaments, and methods of preparation.

6. Claims: (5,6,11,12,17-24,39-41,43,49-53) partially

A binding agent comprising at least the binding domain of interleukin 2 linked to the binding domain of an associated receptor, wherein the binding agent agonises or antagonises the activity of the receptor; said binding agent being a fusion protein; said binding agent wherein both domains are linked by a linker; said linker comprises at least one copy of the peptide "Gly4Ser"; pharmaceutical compositions, uses in the manufacture of medicaments, and methods of preparation.

7. Claims: (5,6,11,12,17-24,39-41,43,49-53) partially

A binding agent comprising at least the binding domain of interleukin 3 linked to the binding domain of an associated receptor, wherein the binding agent agonises or antagonises the activity of the receptor; said binding agent being a fusion protein; said binding agent wherein both domains are linked by a linker; said linker comprises at least one copy of the peptide "Gly4Ser"; pharmaceutical compositions, uses in the manufacture of medicaments, and methods of preparation.

8. Claims: (5,6,11,12,17-24,39-41,43,49-53) partially

A binding agent comprising at least the binding domain of interleukin 4 linked to the binding domain of an associated receptor, wherein the binding agent agonises or antagonises the activity of the receptor; said binding agent being a fusion protein; said binding agent wherein both domains are linked by a linker; said linker comprises at least one copy

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

of the peptide "Gly4Ser"; pharmaceutical compositions, uses in the manufacture of medicaments, and methods of preparation.

9. Claims: (5,6,11,12,17-24,39-41,43,49-53) partially

A binding agent comprising at least the binding domain of interleukin 5 linked to the binding domain of an associated receptor, wherein the binding agent agonises or antagonises the activity of the receptor; said binding agent being a fusion protein; said binding agent wherein both domains are linked by a linker; said linker comprises at least one copy of the peptide "Gly4Ser"; pharmaceutical compositions, uses in the manufacture of medicaments, and methods of preparation.

10. Claims: (5,6,11,12,17-24,39-41,43,49-53) partially; 10 (complete)

A binding agent comprising at least the binding domain of interleukin 6 linked to the binding domain of an associated receptor, wherein the binding agent agonises or antagonises the activity of the receptor; said receptor being the IL-6 receptor or gp 130; said binding agent being a fusion protein; said binding agent wherein both domains are linked by a linker; said linker comprises at least one copy of the peptide "Gly4Ser"; pharmaceutical compositions, uses in the manufacture of medicaments, and methods of preparation.

11. Claims: (5,6,11,12,17-24,39-41,43,49-53) partially

A binding agent comprising at least the binding domain of interleukin 7 linked to the binding domain of an associated receptor, wherein the binding agent agonises or antagonises the activity of the receptor; said binding agent being a fusion protein; said binding agent wherein both domains are linked by a linker; said linker comprises at least one copy of the peptide "Gly4Ser"; pharmaceutical compositions, uses in the manufacture of medicaments, and methods of preparation.

12. Claims: (5,6,11,12,17-24,39-41,43,49-53) partially

A binding agent comprising at least the binding domain of interleukin 9 linked to the binding domain of an associated receptor, wherein the binding agent agonises or antagonises the activity of the receptor; said binding agent being a fusion protein; said binding agent wherein both domains are linked by a linker; said linker comprises at least one copy of the peptide "Gly4Ser"; pharmaceutical compositions, uses

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

in the manufacture of medicaments, and methods of preparation.

13. Claims: (5,6,11,12,17-24,39-41,43,49-53) partially

A binding agent comprising at least the binding domain of interleukin 10 linked to the binding domain of an associated receptor, wherein the binding agent agonises or antagonises the activity of the receptor; said binding agent being a fusion protein; said binding agent wherein both domains are linked by a linker; said linker comprises at least one copy of the peptide "Gly4Ser"; pharmaceutical compositions, uses in the manufacture of medicaments, and methods of preparation.

14. Claims: (5,6,11,12,17-24,39-41,43,49-53) partially

A binding agent comprising at least the binding domain of interleukin 11 linked to the binding domain of an associated receptor, wherein the binding agent agonises or antagonises the activity of the receptor; said binding agent being a fusion protein; said binding agent wherein both domains are linked by a linker; said linker comprises at least one copy of the peptide "Gly4Ser"; pharmaceutical compositions, uses in the manufacture of medicaments, and methods of preparation.

15. Claims: (5,6,11,12,17-24,39-41,43,49-53) partially

A binding agent comprising at least the p35 subunit of interleukin 12 linked to the binding domain of an associated receptor, wherein the binding agent agonises or antagonises the activity of the receptor; said binding agent being a fusion protein; said binding agent wherein both domains are linked by a linker; said linker comprises at least one copy of the peptide "Gly4Ser"; pharmaceutical compositions, uses in the manufacture of medicaments, and methods of preparation.

16. Claims: (5,6,11,12,17-24,39-41,43,49-53) partially

A binding agent comprising at least the binding domain of interleukin 13 linked to the binding domain of an associated receptor, wherein the binding agent agonises or antagonises the activity of the receptor; said binding agent being a fusion protein; said binding agent wherein both domains are linked by a linker; said linker comprises at least one copy of the peptide "Gly4Ser"; pharmaceutical compositions, uses in the manufacture of medicaments, and methods of preparation.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

17. Claims: (5,6,11,12,17-24,39-41,43,49-53) partially

A binding agent comprising at least the binding domain of interleukin 15 linked to the binding domain of an associated receptor, wherein the binding agent agonises or antagonises the activity of the receptor; said binding agent being a fusion protein; said binding agent wherein both domains are linked by a linker; said linker comprises at least one copy of the peptide "Gly4Ser"; pharmaceutical compositions, uses in the manufacture of medicaments, and methods of preparation.

18. Claims: (5,6,11,12,17-24,39-41,43,49-53) partially

A binding agent comprising at least the binding domain of granulocyte colony stimulating factor (G-CSF) linked to the binding domain of an associated receptor, wherein the binding agent agonises or antagonises the activity of the receptor; said binding agent being a fusion protein; said binding agent wherein both domains are linked by a linker; said linker comprises at least one copy of the peptide "Gly4Ser"; pharmaceutical compositions, uses in the manufacture of medicaments, and methods of preparation.

19. Claims: (5,6,11,12,17-24,39-41,43,49-53) partially

A binding agent comprising at least the binding domain of granulocyte macrophage colony stimulating factor (GM-CSF) linked to the binding domain of an associated receptor, wherein the binding agent agonises or antagonises the activity of the receptor; said binding agent being a fusion protein; said binding agent wherein both domains are linked by a linker; said linker comprises at least one copy of the peptide "Gly4Ser"; pharmaceutical compositions, uses in the manufacture of medicaments, and methods of preparation.

20. Claims: (5,6,11,12,17-24,39-41,43,49-53) partially

A binding agent comprising at least the binding domain of ciliary neurotrophic factor (CNTF) linked to the binding domain of an associated receptor, wherein the binding agent agonises or antagonises the activity of the receptor; said binding agent being a fusion protein; said binding agent wherein both domains are linked by a linker; said linker comprises at least one copy of the peptide "Gly4Ser"; pharmaceutical compositions, uses in the manufacture of medicaments, and methods of preparation.

21. Claims: (5,6,11,12,17-24,39-41,43,49-53) partially

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

A binding agent comprising at least the binding domain of cardiostrophin-1 linked to the binding domain of an associated receptor, wherein the binding agent agonises or antagonises the activity of the receptor; said binding agent being a fusion protein; said binding agent wherein both domains are linked by a linker; said linker comprises at least one copy of the peptide "Gly4Ser"; pharmaceutical compositions, uses in the manufacture of medicaments, and methods of preparation.

22. Claims: (5,6,11,12,17-24,39-41,43,49-53) partially

A binding agent comprising at least the binding domain of leukemia inhibitory factor (LIF) linked to the binding domain of an associated receptor, wherein the binding agent agonises or antagonises the activity of the receptor; said binding agent being a fusion protein; said binding agent wherein both domains are linked by a linker; said linker comprises at least one copy of the peptide "Gly4Ser"; pharmaceutical compositions, uses in the manufacture of medicaments, and methods of preparation.

23. Claims: (5,6,11,12,17-24,39-41,43,49-53) partially

A binding agent comprising at least the binding domain of oncostatin M (OSM) linked to the binding domain of an associated receptor, wherein the binding agent agonises or antagonises the activity of the receptor; said binding agent being a fusion protein; said binding agent wherein both domains are linked by a linker; said linker comprises at least one copy of the peptide "Gly4Ser"; pharmaceutical compositions, uses in the manufacture of medicaments, and methods of preparation.

24. Claims: (5,6,11,12,17-24,39-41,43,49-53) partially

A binding agent comprising at least the binding domain of interferon alpha linked to the binding domain of an associated receptor, wherein the binding agent agonises or antagonises the activity of the receptor; said binding agent being a fusion protein; said binding agent wherein both domains are linked by a linker; said linker comprises at least one copy of the peptide "Gly4Ser"; pharmaceutical compositions, uses in the manufacture of medicaments, and methods of preparation.

25. Claims: (5,6,11,12,17-24,39-41,43,49-53) partially

A binding agent comprising at least the binding domain of interferon gamma linked to the binding domain of an associated receptor, wherein the binding agent agonises or

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

antagonises the activity of the receptor; said binding agent being a fusion protein; said binding agent wherein both domains are linked by a linker; said linker comprises at least one copy of the peptide "Gly4Ser"; pharmaceutical compositions, uses in the manufacture of medicaments, and methods of preparation.

INTERNATIONAL SEARCH REPORT

International Application No.

3B 01/02645

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9732891	A	12-09-1997	DE 19608813 A1 WO 9732891 A2 EP 0888384 A2 JP 2000506014 T	18-09-1997 12-09-1997 07-01-1999 23-05-2000
WO 9902552	A	21-01-1999	AU 8127198 A BG 104070 A BR 9812096 A CN 1269835 T EE 200000012 A EP 0991661 A2 WO 9902552 A2 JP 2001509371 T NO 200000086 A PL 338002 A1 SK 62000 A3 ZA 9806145 A HU 0002426 A2	08-02-1999 30-11-2000 18-07-2000 11-10-2000 15-08-2000 12-04-2000 21-01-1999 24-07-2001 08-03-2000 25-09-2000 11-07-2000 07-04-1999 28-11-2000
US 4857637	A	15-08-1989	NONE	
WO 8605804	A	09-10-1986	AT 92961 T AU 5695086 A DE 3688870 D1 DE 3688870 T2 DK 580886 A WO 8605804 A1 EP 0218651 A1 JP 2612264 B2 JP 62502657 T	15-08-1993 23-10-1986 16-09-1993 23-12-1993 03-12-1986 09-10-1986 22-04-1987 21-05-1997 15-10-1987
WO 9005185	A	17-05-1990	WO 9005185 A1 EP 0441889 A1 JP 4503154 T	17-05-1990 21-08-1991 11-06-1992
WO 0018932	A	06-04-2000	AU 6499499 A EP 1115876 A2 NO 20011513 A WO 0018932 A2	17-04-2000 18-07-2001 25-05-2001 06-04-2000
WO 9221029	A	26-11-1992	AT 196548 T DE 69231467 D1 DE 69231467 T2 EP 0586549 A1 JP 6507715 T JP 2001270837 A WO 9221029 A1 US 5506107 A	15-10-2000 26-10-2000 25-01-2001 16-03-1994 01-09-1994 02-10-2001 26-11-1992 09-04-1996
EP 0950710	A	20-10-1999	JP 11285388 A EP 0950710 A2	19-10-1999 20-10-1999
EP 0741187	A	06-11-1996	AU 688210 B2 AU 5197896 A BG 62975 B1 BG 100558 A BR 9602166 A CA 2175298 A1	05-03-1998 14-11-1996 29-12-2000 31-03-1997 13-01-1998 06-11-1996

Form PCT/ISA/210 (patent family annex) (July 1992)

INTERNATIONAL SEARCH REPORT

In International Application No
F01/GB 01/02645

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0741187	A	CN 1157290 A	20-08-1997
		CZ 9601297 A3	15-01-1997
		DE 741187 T1	30-04-1997
		EP 0741187 A2	06-11-1996
		ES 2093593 T1	01-01-1997
		GR 96300075 T1	31-12-1996
		HR 960213 A1	31-10-1997
		HU 9601120 A2	28-11-1996
		JP 9003098 A	07-01-1997
		KR 219970 B1	01-10-1999
		NO 961796 A	06-11-1996
		NZ 286466 A	25-03-1998
		NZ 314957 A	27-05-1998
		PL 314051 A1	12-11-1996
		SG 49337 A1	18-05-1998
		SK 56996 A3	09-04-1997
		TR 960979 A2	21-11-1996
		US 5968779 A	19-10-1999
		US 6025325 A	15-02-2000
		ZA 9603530 A	05-11-1996

Form PCT/ISA/210 (patent family annex) (July 1992)

THIS PAGE BLANK (USPTO)

This Page is inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☒ BLACK BORDERS
- ☒ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☒ FADED TEXT OR DRAWING
- ☐ BLURED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☒ COLORED OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REPERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images
problems checked, please do not report the
problems to the IFW Image Problem Mailbox**

THIS PAGE BLANK (USPTO)